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And Indentifying Pathogenic Variants
Abstract
Inherited retinal degenerative diseases are one of the leading causes of childhood blindness. While over 200
causative genes have been identified, many cases still have an unknown underlying genetic cause. With the
advent of next generation sequencing (NGS), it should be possible to identify the genetic cause in almost
every case, provided enough relatives are willing to participate. However, the massive amount of data
generated by NGS can make identifying the pathogenic variant challenging. It is necessary to filter the data in
order to create a manageable candidate list, but overly strict filtering or erroneous assumptions can result in
filtering out the pathogenic variant. Identifying the genetic cause of retinal degeneration in each patient will
allow us to better identify candidate genes for gene therapy and bring us a step closer to precision medicine.
Here we developed an efficient screening system to find candidate mutations with minimal assumptions to
avoid screening out pathogenic variants and better identify good candidates for novel gene discovery. Out of
an initial cohort of 69 patients we identify the pathogenic variant(s) in 44 of them and identified 11 subjects
as good candidates for novel gene discovery.
We also need a broad treatment for retinal degeneration to help those who have mutations in genes that are
poor candidates for gene therapy or who have an unknown genetic cause. We tested the efficacy of using the
GRM6 minimal promoter as a bipolar cell specific promoter to express channelrhodopsin in bipolar cells after
photoreceptor degeneration to make the bipolar cells directly respond to light. Surprisingly, we found that
unlike in the wildtype mouse retina, the GRM6 promoter is not bipolar cell specific in multiple mouse models
of retinal degeneration. This suggests that the genetic profiles of the cells in the inner retina change during
retinal degeneration. Understanding these fundamental changes in cell specific gene expression during retinal
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GENES AND RETINAL DEGENERATION: CHALLENGES IN OPTOGENETICS 
THERAPY AND IDENTIFYING PATHOGENIC VARIANTS  
Laura M. Bryant 
Jean Bennett M.D., Ph.D. 
 
Inherited retinal degenerative diseases are one of the leading causes of childhood 
blindness.  While over 200 causative genes have been identified, many cases still have an 
unknown underlying genetic cause.  With the advent of next generation sequencing 
(NGS), it should be possible to identify the genetic cause in almost every case, provided 
enough relatives are willing to participate.  However, the massive amount of data 
generated by NGS can make identifying the pathogenic variant challenging.  It is 
necessary to filter the data in order to create a manageable candidate list, but overly strict 
filtering or erroneous assumptions can result in filtering out the pathogenic variant.  
Identifying the genetic cause of retinal degeneration in each patient will allow us to better 
identify candidate genes for gene therapy and bring us a step closer to precision 
medicine.  Here we developed an efficient screening system to find candidate mutations 
with minimal assumptions to avoid screening out pathogenic variants and better identify 
good candidates for novel gene discovery.  Out of an initial cohort of 69 patients we 
identify the pathogenic variant(s) in 44 of them and identified 11 subjects as good 




We also need a broad treatment for retinal degeneration to help those who have mutations 
in genes that are poor candidates for gene therapy or who have an unknown genetic 
cause.  We tested the efficacy of using the GRM6 minimal promoter as a bipolar cell 
specific promoter to express channelrhodopsin in bipolar cells after photoreceptor 
degeneration to make the bipolar cells directly respond to light.  Surprisingly, we found 
that unlike in the wildtype mouse retina, the GRM6 promoter is not bipolar cell specific 
in multiple mouse models of retinal degeneration.  This suggests that the genetic profiles 
of the cells in the inner retina change during retinal degeneration.  Understanding these 
fundamental changes in cell specific gene expression during retinal degenerative 
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Chapter 1: Introduction 
Phenotype and genotype variability in inherited retinal degeneration 
Hereditary retinal degeneration causes blindness independent of environmental factors, 
with disease onset often occurring during childhood.  This includes non-syndromic forms 
like Stargardt disease, Leber’s congenital amaurosis (LCA), retinitis pigmentosa (RP), 
achromatopsia and cone-rod dystrophy (CORD) as well as syndromic forms like Bardet-
Biedl syndrome (BBS), Usher’s syndrome and Batten disease.  Typically, hereditary 
retinal degeneration is monogenic and has an earlier onset than other causes of retinal 
degeneration like glaucoma or age related macular degeneration.  In some forms, such as 
LCA, disease onset is very young, before the age of 5
1
.  Others, like RP and Stargardt can 
have an adult onset
2,3
.  Retinal dystrophy can be inherited in every known inheritance 
pattern including autosomal dominant (sometimes with incomplete penetrance), 
autosomal recessive, X-linked and sporadic.  There is a huge variability in disease 
presentation and progression.  Stargardt disease primarily affects cones while RP 
primarily affects rods
4,5
. More severe diseases like LCA start by affecting rods but 
eventually cause secondary cone degeneration
6
.  Other forms, such as cone dystrophy, 
largely preserve rod function, even in the most advanced disease state
7
.  Some forms of 
retinal degeneration cause different patterns of degeneration or include deposits in the 
subretinal space.  The hallmark feature of Stargardt disease is yellow flecks in the 
macula, which are lipofuscin deposits in the subretinal space
3,4,8
.  This is not seen in other 




retinal pigment epithelial (RPE) cells after photoreceptor degeneration, are characteristic 
of retinitis pigmentosa
9
.   
Despite the huge variability seen in different forms of retinal degeneration, there is also 
significant overlap in disease phenotype which can affect the ability to give an accurate 
and specific diagnosis in early stages of degeneration. In particular, syndromic retinal 
degeneration can appear to be non-syndromic in early stages if other symptoms have not 
yet appeared or if patients fail to report the other symptoms to the ophthalmologist.    
Bardet Biedl syndrome is extremely variable in severity and mild forms can be initially 
diagnosed as RP
10
.  Cone dystrophy can progress to cone rod dystrophy in some cases 
while in other cases rods are spared
11
.   Since the only difference is disease progression, 
an ophthalmic exam during the early stages of the diseases cannot always provide an 
exact diagnosis.  When the diagnosis is being made based on the time of disease onset 
and severity of degeneration, it is possible that a genetic diagnosis can modify the initial 
clinical diagnosis, such as changing an initial diagnosis of RP to a late onset form of LCA 
or an initial diagnosis of BBS can be changed to RP after clinical reassessment
12,13
. 
In addition to the phenotypic variability in retinal degeneration, there is significant 
genetic variability within the same phenotype.  There are currently 18 genes known to 
cause LCA, with a significant number of patients with no known genetic cause
14-18
.  
Retinitis Pigmentosa can be caused by mutations in any one of over 60 genes, with 
approximately 40% of cases negative for all known causes of RP
19,20
.  Other forms have 
less genetic variability.  Stargardt disease, for example, is almost always caused by 
mutations in ABCA4 (95% of cases)
21




can cause more than one form.  For example, although ABCA4 causes most cases of 
Stargardt disease, it can also lead to retinitis pigmentosa or cone-rod dystrophy or even 
act as a disease modifying allele
22-24
.  The same mutation in PRPH2 can cause autosomal 
dominant RP or macular degeneration even within the same family
25
.  Variants in USH2A 
have been shown to cause both Usher syndrome and RP
26
.  These are only a few of many 
examples of genes that can cause more than one phenotype. 
Possibilities for polygenic inheritance 
To further complicate the genetics of retinal degeneration, digenic inheritance is another 
possible mode of inheritance.  So far only one digenic cause of retinal degeneration has 
been identified (ROM1 and PRPH2), but it is likely that at least some of the remaining 
cases of undetermined genetic cause will be digenic or polygenic
27
.  Recently, a second 
potential cause of digenic retinal degeneration (this time causing syndromic retinal 
dystrophy) was proposed that is caused by null alleles in RP1L1 and C2orf71, but more 
has to be done to conclusively prove that heterozygous mutations in these two genes are 
sufficient to cause retinal degeneration in humans
28
. 
While there is so far only one known cause of digenic inheritance, modifying alleles are 
much more common and contribute to the phenotypic variability we see with some genes.  
Heterozygous mutations that would not cause retinal degeneration by themselves have 
been shown to contribute to disease pathogenesis when combined with a pathogenic 
mutation, either alleviating or aggravating the disease phenotype.  ABCA4 and ROM1 can 






RPGRIP1L can act as a modifying allele in ciliopathies to exacerbate (or cause) a retinal 
phenotype
29
.  While not pathogenic in isolation, these mutations are very important to 
note and can help provide a more accurate clinical diagnosis and prediction of disease 
progression.  They can be particularly important in cases of autosomal dominant 
inheritance with incomplete penetrance.  In those cases, modifying alleles can prevent 
development of the disease in individuals carrying the pathogenic variant.  For example, 
variants in PRPF31 can cause autosomal dominant retinitis pigmentosa through 
hemizygous insufficiency
30
.  However, a variant in CNOT3 upregulates the expression of 
PRPF31, thereby increasing the expression of the wildtype allele to a level that is 
sufficient to meet the needs of the cell.  Family members with the  
How different cell types contribute to retinal degeneration 
Typically mutations that cause retinal degeneration are in genes expressed in the 
photoreceptors or the retinal pigment epithelium (RPE), although not necessarily 
exclusively expressed in those cell types.  Photoreceptor degeneration is often the first 
stage of retinal degeneration, so it follows that mutations in photoreceptor genes can 
directly affect photoreceptor viability.  The RPE provides structural and trophic support 
to the photoreceptors, and mutations there can also have a direct impact on photoreceptor 
viability.  Rarely, mutations in genes in the choroid, like CA4, can also cause retinal 
degeneration through a more complicated mechanism.   
Photoreceptors are uniquely susceptible to degeneration due to their high metabolic load, 
high protein turnover and unique structure
32-34




containing stacks of membrane (called discs) and is connected to the cell body by the 
connecting cilium
35
.  Each disc contains the proteins needed for phototransduction
36
.  All 
of the proteins in the outer segment must be trafficked through the connecting cilium
37
.  
Any deficit in cilia trafficking (such as those caused by mutations in RPGR, ALMS1 or 
ARL3) can have a profound detrimental effect on the outer segments.  The structure of the 
outer segment ensures that almost every particle of light will hit a disc and induce the 
phototransduction cascade but it also makes the cell particularly dependent on the 
primary cilia.  Mutations in genes responsible for cilia structure and maintenance (such as 
CEP29 and, MAK) or in disc structure (like PRPH2 and ROM1) can cause retinal 
degeneration by destabilizing the outer segment or prevent the outer segment from 
forming properly
38
.  Mutations in proteins involved in the phototransduction cascade 
(such as RHO, SAG and PDE6B) prevent proper regulation of the ion channels involved 
in phototransduction
39
.  Excess or deficiency in ions, especially calcium, can induce 
apoptosis
40
.  Mutations in transcription factors like CRX and NR2E3 result in 
photoreceptor degeneration by impairing and altering development, thereby preventing 
proper photoreceptor formation
41,42
.  Meanwhile, mutations in splicing factors (which 
include PFPF3, PRPF8 and PRPF31) appear to affect photoreceptor viability more 
indirectly
43
.  It is still unknown why mutations in ubiquitously expressed splicing factors, 
which are required by every cell type, can cause tissue specific deficits.  One theory is 
that the especially high protein turnover in the photoreceptors is responsible for their 
unique susceptibility to heterozygous mutations in splicing factors
44
.  The discs in the 
outer segments have constant turn over as the older discs are phagocytized by the RPE
45
.  




proteins.  If splicing is impaired, it is hypothesized that not enough of these proteins are 
produced resulting in destabilized discs or dysfunctional phototransduction.  
Interestingly, while mutations in proteins involved in most of these cellular functions are 
either recessive or a mix of dominant and recessive, all known mutations in splicing 
factors that cause retinitis pigmentosa are dominant due to haploinsufficincy
46
.   
Genes expressed primarily or exclusively in the RPE can also cause retinal 
degeneration
47
.  The RPE provides trophic support to the photoreceptors
48
.  Mutations in 
genes involved in metabolic support to the retina will have a direct impact on 
photoreceptor viability.  The RPE  also plays a critical role in the retinoid cycle, which is 
essential in order to provide 11-cis-retinal (a necessary substrate for phototransduction) to 
the photoreceptor outer segments
49
.  During phototransduction, 11-cis-retinal is converted 
to all-trans-retinal and the RPE must convert it back to 11-cis-retinal before sending it 
back to the phtoreceptors
49
.  This process can be disrupted by mutations in enzymes and 
transport proteins in the RPE including RPE65, IRBP, RDH5 and LRAT
50
.  The RPE also 
plays a necessary role in disc turnover
51
.  Preventing efficient phagocytosis of 
photoreceptor outer segments (such as by mutations in MERTK) can be toxic to the 
photoreceptors
52
.   
Mutations in the choroid, the vascular layer of the eye, can also cause retinal 
degeneration but are much less common than mutations in the RPE or photoreceptors.  
CA4 mutations cause RP by preventing proper pH balance in the eye
53
.  Gyrate atrophy, 
which causes choroid and retinal atrophy, is caused by mutations in OAT.  Ornithine 






.  These causes of retinal degeneration are very rare and it is unlikely 
that many of the unidentified causes of retinal degeneration are from genes expressed 
primarily in the choroid. 
Next generation sequencing for inherited retinal degeneration 
It used to be very expensive and time consuming to identify the disease causing 
mutation(s) in patients with retinal degeneration.  Unlike diseases like cystic fibrosis that 
only have one gene to screen for mutations, over 140 genes have been identified that 
cause retinal degeneration with a significant number of genes still unknown
33
.  With the 
advent of next generation sequencing (NGS), sequencing a large number of genes has 
become much quicker and more affordable than it was previously
55
.  Clinically, APEX 
microarray chips are often used to identify specific mutations in specific genes that are 
known to cause disease
56
.  This can be an effective tool if the patient has one of the 
mutations screened for on the chip.  However, chip arrays miss new mutations in the 
genes that are being screened since they look specifically for the identified pathogenic 
single nucleotide polymorphisms (SNPs)
57
.  Sequencing is a much more thorough way to 
screen for mutations in the genes that have already been identified
56
. Furthermore, being 
able to sequence the entire genome facilitates novel gene discovery and will help to fill in 
the gaps of our current knowledge about the genetics of retinal degeneration. 
Novel gene discovery is beneficial for both translational and basic science.  It allows us 
to better identify patient populations for clinical trials and to prioritize genes based in part 




that are tolerated or not tolerated, we can better understand which domains are important 
to the function of the protein.  By finding the genes in which mutations cause retinal 
degeneration, we gain a better understanding of how the retina works and what function 
those proteins have in the retina.   
Whole genome sequencing (WGS) is the most thorough way to screen for novel 
mutations
58
.  It allows us to find deep intronic mutations, mutations in splice sites, 
mutations in regulatory regions, as well as mutations in the actual genes
59,60
.  However, 
that level of genomic coverage is not always needed.  The majority of disease causing 
mutations are in the exome, the protein coding portion of DNA.  The exome makes up 
only about 2% of the human genome.  Initial screening with whole exome sequencing 
(WES) could eliminate the need for more extensive sequencing in most patients.  WES 
can detect both mutations in the exome as well as the adjacent splice sites
61
.  Both WGS 
and WES can identify SNPs and small insertions and deletions.  One major caveat of next 
generation sequencing is that it is not ideal for finding large insertions and deletions.  
WGS is better at detecting copy number variants (CNVs) than WES, but both require a 
significant depth of coverage to detect CNVs reliably.   
WES analysis has two main stages.  First, the reads must be mapped onto the human 
genome and the variants identified and annotated.  This part of the process can now be 
largely automated and the output is a list of areas where the reference genome is different 
from the patient’s genome, annotated with the observed frequency in that variant in 
databases like ExAC and the 1000 Genomes Project as well as the expected effect on the 
protein
62-66






.  Sorting through the variants to identify likely pathogenic variants cannot yet 
be automated and requires a lot of assumptions to create a manageable list of candidate 
genes
68
.  Some filters can be applied easily to the dataset without a high likelihood of 
filtering out the pathogenic variant
69
.  For example, filtering by frequency of the variant 
is a good first step.  When dealing with a rare monogenic disease, a variant with a high 
frequency is unlikely to be involved
69
.  Removing all synonymous variants, variants that 
have no effect on protein sequence, is another filter that is unlikely to remove pathogenic 
variants
68
.  Filtering for genes expressed in the affected tissue can also be beneficial. 
However this list is still too long to go through every variant by hand to check for likely 
pathogenic variants. Developing effective filters for retinal degeneration will help to 
more quickly and accurately identify the pathogenic mutations in the patients screened 
with WES. 
Our goal is not only to identify the cause of retinal degeneration but ultimately to treat it.  
Gene therapy is a promising approach for treating hereditary retinal degeneration.  If 
there is a loss of function mutation, a new copy of the gene can be inserted into the cell so 
that the protein is produced and degeneration is halted.  The first gene therapy for retinal 
degeneration recently completed phase III clinical trials
70
.  It is for LCA patients with 
mutations in RPE65, which is an ideal candidate for gene therapy.  The gene has a short 
coding sequence, does not require large amounts of expression to be effective, is not toxic 
when overexpressed, is expressed in an easy to transduce cell type and has a relatively 
wide window for treatment
71-73
.  Additionally, treating mutations in the RPE does not 




cell supports multiple photoreceptors (with a 20:1 photoreceptor:RPE ratio in the fovea) 
thereby saving more cells per RPE cell transduced, while correcting a defect in the 
photoreceptor would mainly help the cells that are actually transduced
74
. 
Unfortunately, not all genes are good candidates for gene augmentation therapy.  Some 
genes, like USH2A and ABCA4, are simply too big for most current vectors.  Adeno-
associated virus (AAV), the most common vector and the one used in the RPE65 trial, 
can only package about 4.7 kb which includes the ITRs, promoter and cDNA sequence of 
the gene
75
.  USH2A is over 15 kb while ABCA4 is over 6 kb
76,77
.  Even without taking 
into account the space needed for a promoter it is obvious that these genes cannot be 
packaged in AAV.  Furthermore, some genes are toxic if overexpressed or require a high 
level of expression to prevent degeneration
78
.  Currently, we do not have the ability to 
finely tune expression levels to make them match the exogenous expression levels, 
although we can select weaker, cell specific promoters to limit toxicity.  Unfortunately, 
using a weaker promoter would  risk lowering the expression level below the therapeutic 
threshold.  Treating a dominant gain-of-function mutation is even more complicated.  It 
requires specific knock down of the mutant allele, which may vary from the wildtype 
allele by a single nucleotide.  The clustered regularly interspaced short palindromic 
repeats (CRISPR) system or RNA interference (RNAi) may be able to be used in these 
cases, but depending on the mutation, it may not be possible to achieve the needed level 
of specificity with current technology
79,80
.  Finally, there are too many different genes, 
some of which affect only a handful of patients, for it to be feasible to develop a specific 




Optogenetic therapy to restore vision 
Optogenetic therapy is a generic treatment that has the potential to restore visual function 
to the retina regardless of the genetic cause of disease
81
.  Although it is unlikely to result 
in the same level of visual restoration as gene augmentation due to the inherent 
limitations in image resolution, it would be applicable for every genetic cause rather than 
only one and would not be impacted by the number of patients with a particular mutation, 
size of the defective gene or the narrow treatment window to preserve photoreceptors
81
.  
Optogenetic therapy works by inserting a light sensitive ion channel into the desired cell 
type so that it hyperpolarizes or depolarizes the cell directly in response to light
82,83
.  
Essentially, the goal of optogenetic therapy is to turn other cell types in the retina into 
photoreceptors after the photoreceptors have died or stopped functioning.   
There are several potential targets for optogenetic therapy.  The four most promising 
possibilities are: remnant cone cell bodies, ON bipolar cells, AII amacrine cells and 
ganglion cells
81
.  Targeting halorhodopsin to remnant cone cell bodies induces them to 
hyperpolarize in response to light, mimicking their normal light response
84
.  Remnant 
cone cell bodies are cone photoreceptors which no longer have outer segments.  They 
would not be as sensitive to light as normal photoreceptors or have as large of a response, 
but all retinal processing would be preserved.  Early studies in mice have successfully 
used this approach to restore light mediated behavioral responses as well as the 
electrophysiological response to light in the retina
85
.  However, eventually the remnant 




treatment option.  Optogenetic therapy is designed to restore function, not to halt or even 
slow cell death.   
The second most attractive target is ON bipolar cells.  If channelrhodopsin is expressed in 
ON bipolar cells, the cells depolarize in response to light
86-88
.  Normally the ON bipolar 
cells would depolarize in response to the decrease in glutamate release from the 
photoreceptors.  Like all optogenetic therapy, the light sensitivity is lower than what is 
seen in healthy photoreceptors, but with the advancements being made in engineering 
more sensitive channelrhodopsins this will become less of a problem
89,90
.  We can 
specifically target ON bipolar cells by using the GRM6 promoter
86
.  This helps to retain 
more of the retinal processing since the OFF pathway would not be activated, which 
could confuse or cancel out the signal.   
Targeting the AII amacrine cells would allow activation of the ON pathway as well
81
.  
AII amacrine cells connect the rod bipolar cells to the cone bipolar cells91.  They 
depolarize in response to glutamate release from the rod bipolar cells
92
.  AII amacrine 
cells are connected to ON cone bipolar cells by gap junctions, causing the ON cone 
bipolar cells to depolarize as well
92
.  In addition to the excitatory output to the ON 
pathway, AII amacrine cells form inhibitory synapses with OFF bipolar cells thereby 
simultaneously exciting the ON pathway and inhibiting the OFF pathway
92
.  Targeting 
AII amacrine cells may allow for more inhibition of the OFF pathway while retaining the 




Ganglion cells are the final target for optogenetic therapy
93,94
.  Ganglion cells are the 
cells responsible for retinal output to the brain.  Targeting ganglion cells would remove 
all or most retinal processing of the visual signal.  However, retinal degeneration and 
retinal remodeling are less likely to affect the quality of the visual signal over time.  
Currently we do not have promoters that are specific to ON vs OFF ganglion cells and 
instead must target both and hope that the neuroplasticity is able to adjust to the new 
input (an OFF cell becoming an ON cell).  
The final strategy for optogenetic therapy is to use a ubiquitous promoter that will turn 
any cell transduced into a photoreceptor cell
85,95
.  The advantage of this strategy is the 
higher expression levels achieved by ubiquitous promoters.  More cells total would be 
responding to light which could increase the sensitivity of the treated retina.  However, 
both the ON and OFF pathways would be activated simultaneously.  Activating an 
excitatory and inhibitory cell at the same time could cause them to cancel out or at least 
diminish the signal.  We do not know the limits of retinal plasticity and brain plasticity so 
it is undetermined whether a completely non-targeted therapy would result in a usable 
retinal signal or if the brain would interpret it as essentially gibberish.   
Retinal remodeling and optogenetic therapy 
One of the most important factors for successful optogenetic therapy is understanding the 
effect of retinal remodeling on the therapy (and vice versa).  There is a lot that we still do 
not understand about retinal remodeling.  It used to be assumed that the inner retina 




late stages of retinal degeneration the inner retina can undergo profound changes
96-101
.  
Studies in rd10 mice have been done which detail some of the effects of retinal 
remodeling
102,103
.  Rd10 mice have a fast rate of retinal degeneration with only a single 
layer of photoreceptors remaining at P45
102
.  The first sign of retinal remodeling is 
retraction of the rod bipolar cell dendrites and mislocalization of mGluR6 from the 
dendrites to the cell body and axon
103
.  While inner retinal cell death is much slower than 
photoreceptor degeneration, about a quarter of the rod bipolar cells and horizontal cells 
degenerated after 9 months in the rd10 mice
103
.   Various cell types start to migrate to 
new positions, including RPE cells invading the neural retina, ganglion cells migrating 
into the inner plexiform and inner nuclear layers, and bipolar cells migrating up to the top 
of the inner nuclear layer
98
.  Ectopic synapses form between all cell types and the 
expression profiles of the cells change
98,104
.  These changes have the potential to greatly 
affect the long term efficacy of optogenetic therapy.   
Overall, in order to better treat retinal degeneration, we need to thoroughly understand 
both the genetics of retinal degeneration as well as the changes that occur to the retina 
over the course of retinal degeneration.  Tools like whole exome sequencing and 
optogenetics are allowing us to evaluate the degenerate retina more thoroughly than was 
previously possible.  Here, we develop a screening process for whole exome sequencing 
data to identify pathogenic mutations using genes known to be linked to retinal 
degeneration and identify subjects who are good candidates for novel gene discovery.  
We also evaluate the utility of the GRM6 promoter for optogenetic therapy targeting ON 




shows that the GRM6 promoter does not remain specific to bipolar cells in advanced 
stages of retinal degeneration.  The work presented here will help us to better understand 
both the genetic cause and subsequent genetic regulation within the retina and hopefully 
bring us closer to being able to effectively treat inherited retinal degeneration.   
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Abstract:   
Background:  Accurate clinical diagnosis and prognosis of retinal degeneration can be 
aided by the identification of the disease causing genetic variant.  It can confirm the 
clinical diagnosis as well as inform the clinician of the risk for potential involvement of 
other organs such as kidney disease.  It also aids in genetic counselling for affected 
individuals who want to have a child.  With the advent of next generation sequencing, 
identifying pathogenic mutations is becoming easier, especially the identification of 
novel pathogenic variants. 
Methods:  We used whole exome sequencing on a cohort of 69 patients with various 
forms of retinal degeneration.  All potential pathogenic variants were verified by Sanger 
sequencing and, when possible, segregation analysis of immediate relatives.  Potential 
variants were identified by using a semi-masked approach in which rare variants in 
candidate genes were identified without knowledge of the clinical diagnosis (beyond 
“retinal degeneration”) or inheritance pattern.  After the initial list of genes was 
prioritized, genetic diagnosis and inheritance pattern were taken into account. 
Results:  We identified the likely pathogenic variants in 64% of the subjects.  7% had a 
single heterozygous mutation identified that would cause recessive disease and 13% had 
no obviously pathogenic variants and no family members available to perform 
segregation analysis.  Eleven subjects are good candidates for novel gene discovery.  




Conclusion:  Whole exome sequencing allows for through genetic analysis of candidate 
genes as well as novel gene discovery.  It allows for an unbiased analysis of genetic 
variants to reduce the chance that the pathogenic mutation will be missed due to 
incomplete or inaccurate family history or analysis at the early stage of a syndromic form 
of retinal degeneration. 
Keywords: retinal degeneration, genetic diagnosis, retinitis pigmentosa, Leber congenital 




Introduction:   
Many forms of retinal degeneration result from genetic mutations including Leber’s 
congenital amaurosis (LCA), retinitis pigmentosa (RP), Stargardt’s disease and cone-rod 
dystrophy.  Many different genes have been discovered that, when mutated, lead to 
retinal degeneration.  For LCA alone, mutations in 18 different genes have been 
discovered to be pathogenic, with about 30% of cases having no known genetic cause
1,2
.  
Retinitis pigmentosa can be caused by mutations in any one of over 80 different genes 
with many cases still having an unknown cause
3-5
.  While there has been great progress in 
identified disease-causing mutations for retinal degenerative diseases, this presents a 
staggering problem to the clinician: what is the most efficient and cost-effective test for 
identifying the genetic diagnosis? 
Discovering genes that cause retinal degeneration when mutated and the specific 
mutations that do or do not cause disease is important to advancing the field.  If the 
pathogenic mutation(s) can be identified in every patient with retinal degeneration we 
will know how prevalent those mutations are, will be able to provide accurate prognoses, 
and will be better able to define potential patient populations for clinical trials.  With the 
growing potential of novel strategies using gene editing (such as use of Clustered 
Regulatory Interspaced Short Palindromic Repeats (CRISPR)) to correct specific genetic 
mutations, identifying not only the gene but the specific mutations in each patient is 
becoming even more important. Identifying pathogenic variants in retinal degeneration 
benefits basic science as well as clinical research.  By identifying the genes that result in 




works, which proteins are necessary for the various cellular processes that take place in 
the retina, and how they interact.  By defining the specific mutations that are pathogenic 
(and which ones are tolerated) we better understand the function of those proteins and 
domains. This information can also be used to develop gene-based treatments (i.e. gene 
therapy). 
The present report reviews our own experience in seeking genetic diagnoses for retinal 
degeneration patients seen over a 5 year period at ophthalmology clinics at the University 
of Pennsylvania School of Medicine and The Children’s Hospital of Philadelphia as well 
as other patients who self-referred who agreed to participate in our molecular genetic 
research study. We carried out preliminary screens of these individuals in an attempt to 
identify known disease-causing variants. We followed up with whole exome sequencing 
(WES). Finally, we assessed the efficiency of making the correct genetic diagnosis using 
these techniques. 
Methods:  
Recruitment: Individuals seen in the Scheie Eye Institute and The Children’s Hospital of 
Philadelphia retina clinics who were found to have a degenerative condition (and first 
degree relatives) were invited to submit a blood sample for molecular genetics research 
testing. Study procedures were approved by the University of Pennsylvania IRB 





Whole Exome Sequencing: 
Purified, target enriched genomic samples from 69 patients with various form of retinal 
degeneration (including LCA, RP, Stargardt’s disease, cone rod dystrophy and 
achromatopsia) to the Penn Genome Frontiers Institute (PGFI) were evaluated by whole 
exome sequencing (see table 2-1).  Samples had previously been screened using Asper 
Ophthalmics (Tartu, Estonia) arrayed primer extension multi-gene panels for the relevant 
disease and no disease-causing variants had been identified. Target enrichment was 
performed with the Agilent SureSelect target enrichment system (Agilent Technologies, 
Santa Clara, CA)and the sequencing was performed on Illumina HiSeq2000 (San Diego, 
CA). 
Mapping and variant identification: 
Mapping and variant identification was performed using Galaxy
6
.  The FASTQ files for 
each patient were mapped to the reference human genome (hg18) using Burrows-
Wheeler Aligner for Ilumina (BWA for Ilumina).   Variants were identified using 
freebayes
7
.    Variants were annotated using Annovar
8
.   
Identifying variants of interest: 
A semi-masked analysis was used to identify potentially pathogenic mutations without 
knowledge of the type of retinal degeneration.  We created a curated list of genes linked 
to any form of retinal degeneration and used a python script (www.python.org) to create a 
customized list of potential pathogenic variants  for each patient. That list consisted of 




mutations were then prioritized based on mutation type and known facts about the 
mutations from dbSNP (https://www.ncbi.nlm.nih.gov/projects/SNP/) and the Universal 
Protein Resource (UniProt; http://www.uniprot.org) (known to be benign, known to be 
pathogenic, novel variant, etc.).  We then checked if the variants were consistent with the 
clinical diagnosis and performed segregation analysis when possible.   
We verified the possible pathogenic mutations in the patients and relatives via PCR using 
Phusion polymerase (New England Biolabs; Ipswich, MA) and custom primers made by 
Invitrogen (Carlsbad, CA) followed by Sanger sequencing by the Penn Genomics 
Analysis Core.  The sequences were visualized using SnapGene software (from GSL 
Biotech, Chicago, IL; available at snapgene.com). 
Results: We identified the pathogenic mutations in 44 of the subjects (65%).  66 different 
mutations were found in 26 different genes.  18 of these mutations are completely novel 
and not listed in dbSNP.  11 more are extremely rare, have no prediction on pathogenicity 
and are not in any published study (See supplement for specific mutations in each form of 
retinal degeneration).   
De Novo Mutations: 
De novo mutations pose a particular problem when trying to identify pathogenic 
mutations.  Dominant de novo mutations appear to be recessive when looking at the 
family history.  We found two de novo mutations in our patient cohort.  The first was a 
novel frameshift mutation in OTX2, a known mutational hotspot, in a patient with Leber’s 




essential for development of the brain and retina.   All known mutations are autosomal 
dominant.  Knockout of OTX2 is embryonic lethal in mice due the absence of the 
forebrain and midbrain
9
.  OTX2 is essential for photoreceptor differentiation as well as 
pituitary development.  Knockout of OTX2 in mouse retinal cells results in a failure to 
develop photoreceptors
10
.  OTX2 mutations can result in syndromic microphthalmia, 
combined pituitary hormone deficiency, and early-onset retinal dystrophy with or without 
pituitary dysfunction
11-13
.  The frameshift mutation was not present in either parent.   
Another subject presented with cone dystrophy beginning at age 15.  Neither parent had 
any form of retinal degeneration so it was presumed that the genetic cause was recessive.  
Upon analysis of the WES dataset, we found that the proband was heterozygous for a 
p.Y99C mutation in GUCA1A (Table 2-2, JB185), a well characterized dominant 
mutation leading to cone dystrophy
14
.  Neither parent carried the p.Y99C mutation.  
Paternity was confirmed using the whole exome sequencing results of the parents and 
proband, indicating that the p.Y99C mutation was a de novo mutation.   
Identification of KIF7 as a candidate gene for cone dystrophy: 
A 5yo boy with cone dystrophy was found to have a compound heterozygous mutation in 
KIF7 (p.H1115Q and p.Q834R)(Table 2-2; JB307).  KIF7 is a cilia gene that plays an 
important role in hedgehog signaling and microtubule stability
16,17
.  KIF7 localizes to the 
primary cilia, specifically the distal tip
18
.  Mutations in KIF7 cause the cilia to become 
longer than normal and disorganized
18
.  Knockout of KIF7 in mice is neonatal lethal
17
.   




syndrome, hydrolethalus syndrome, acrocallosal syndrome, Meckel-Gruber syndrome 
and BBS
19
.   Both variants in the patient in this study have been previously identified as 
hypomorphic variants and have been seen in patients with BBS, Meckel-Gruber 
syndrome and hydrolethalus syndrome
20
.  Typically, when a missense mutation in KIF7 
leads to disease, the other allele is a null allele with either a truncation or frameshift 
mutation
20,21
.  In this case, both alleles are rare hypomorphic variants (allele frequency in 
1000 Genomes are 0.0010 and 0.0058 for p.Q834R and p.H1115Q respectively).  In 
addition to the compound heterozygous mutations, the subject was heterozygous for 
mutations in several other cilia genes, including a pathogenic mutation in BBS1.  
Ciliopathies have been shown to have a range of severities depending on the mutation in 
the gene.  For example, CEP290 mutations can result in retinal degeneration alone 
(specifically LCA), syndromic ciliopathies (Joubert syndrome or Meckel syndrome) and 
neonatal lethal ciliopathies.  This range appears to be due the amount of functional 
CEP290 that remains
22
.  KIF7 could be similar to CEP290 in that severe mutations like 
truncations and frameshifts result in more severe ciliopathies while compound 
heterozygosity of hypomorphic variants may result in only retinal degeneration.   
Additional mutations: 
Some of the patients had potentially pathogenic mutations in additional genes linked to 
retinal degeneration.  Most of these additional mutations were heterozygous and therefore 
unlikely to be the disease causing mutation in the patient.  However, it is possible that the 
heterozygous mutations, which can be tolerated in isolation, add to the mutational load 
and modify the patient’s phenotype
23




additional mutations (see tables 2-4 and 2-5).  Some of the mutations are in genes that 
interact or are in the same pathway, increasing the chances of epistatic effect.  
No disease causing variants identified: 
We were unable to conclusively determine the disease causing variants in 20 subjects in 
the study.  Five of these had a presumably recessive disease with one pathogenic or likely 
pathogenic variant identified that is consistent with their disease phenotype (see table 2-
3).  These patients should be screened for copy number variants (CNVs) in the gene 
identified or possibly for intronic variants.  Of the remaining 20 subjects, 9 do not have 
family members willing to enroll in the study.  Since we did not find any obviously 
pathogenic variants in the initial screening and are unable to perform segregation analysis 
for the variants identified, we are unable to determine the pathogenicity of the variants 
identified.  One of these subjects has many known pathogenic, likely pathogenic and 
novel variants but all are inconsistent with the diagnosis of adRP and we are unable to 
perform segregation analysis to narrow down the disease causing variant(s) (see table 2-
5).  The remaining 10 subjects should be analyzed for novel genes that could cause retinal 
degeneration (see figure 2-1). 
Discussion:  
Whole exome sequencing is a powerful tool to help identify new mutations in patients 
who test negative for the known pathogenic mutations for retinal degeneration.  However, 
the majority of mutations in these patients are in genes already linked to retinal 




negative screenings using gene panels for their disease, were found to harbor pathogenic 
mutations in genes already linked to retinal degeneration.  Thus, we found that if we 
failed to find the pathogenic mutation in a patient with retinal degeneration using 
standard APEX microarrays for their disease, it could be more time and cost efficient to 
use targeted sequencing of all genes linked to retinal degeneration rather than whole 
exome sequencing. Using a targeted sequencing approach would also allow good 
coverage of the area of interest without the expense of deeper coverage of the whole 
exome.  When we restricted our analysis of the whole exome sequencing data to genes 
linked to retinal degeneration, it allowed us to find novel mutations in those genes as well 
as mutations that cause a different form of retinal degeneration.   
WES is a powerful tool for identifying pathogenic mutations in genes by quickly 
identifying all variants in a patient’s exome.  It sequences the entire protein coding 
portion of the genome, which is about 2% of the total genome.  Since the non-coding 
portion is not sequenced, it is cheaper than whole genome sequencing (WGS) and allows 
for greater depth of coverage.  The large majority of disease-‘causing variants are in the 
exome, so although intronic mutations are missed, it is still usually more cost effective to 
use WES and follow up with WGS or targeted sequencing if WES fails to identify the 
cause of disease.   
Although the size of the dataset generated by WES is smaller than WGS, sorting through 
the large amount of data generated to find the relevant variants is still a challenge.  
Filtering the dataset based on inheritance pattern, disease phenotype, and other 




pathogenic variants.  De novo mutations can result in a dominant mutation in a patient 
whose disease is presumed to be recessive. Dominant mutations can also be revealed by 
findings of non-paternity (and concomitant incorrect family history). Diagnosis is based 
on qualitative assessment and psychophysical testing and many forms of retinal 
degeneration have significant phenotypic overlap with each other.  A patient can be 
diagnosed with a non-syndromic form of retinal degeneration when they have a 
syndromic form if they have not yet developed extra-ocular symptoms.  In these cases it 
is easy to filter out pathogenic variants if the filters are too strict. 
Limiting our initial screening to the genes that are known to cause one particular form of 
retinal degeneration would have been unnecessarily restrictive.  It would have placed too 
much confidence in the accuracy of the clinical diagnosis when there is significant 
overlap between different forms of inherited retinal degeneration. Further, at both early 
and late stages of retinal degeneration, it may be difficult to distinguish one form of 
disease from another.  The possibility of de novo mutations and inaccurate family history 
makes it impossible to determine the inheritance pattern with complete certainty even in 
the best case scenario.  There are also multiple genes that are linked to multiple forms of 
retinal degeneration, with the mechanism by which they can differentially affect rods and 
cones still not understood.  It is entirely possible that a gene in which mutations are 
known to cause only RP or LCA currently could in fact also have mutations that lead to 
cone dystrophy.  When one adds in the possibility of digenic cause and epistatic effects, it 
becomes even clearer that limiting analysis by the form of retinal degeneration is overly 




So far, most of the mutations we have found that lead to retinal degeneration follow 
typical Mendelian genetics.  However, many patients with retinal degeneration do not 
have a known cause.  It is probable that at least some of these cases will be found to be 
due to the additive or epistatic effects of mutations in more than one gene.  Especially in 
the case of a presumed recessive inheritance pattern, the possibility that the cause is 
polygenic rather than monogenic cannot be discounted.  In light of that possibility, 
screening all genes with mutations known to cause or contribute to retinal degeneration is 
important.  The fact that these genes code for proteins vital to the proper functioning of 
the retina has already been established.  A mutation or variant in a gene that reduces the 
ability to function (but not so much that it is sufficient to cause disease in the general 
population) might very well add to the mutational load that predisposes someone to 
retinal degeneration.   
By using a semi-masked analysis in our screening, we were able to easily identify two 
patients with dominant de novo mutations as well as several with an inaccurate or 
incomplete incoming diagnosis.  Many of the subjects in our study self-reported the 
initial diagnosis, which decreases the initial accuracy.  However, there is some inherent 
unreliability in the initial diagnosis for early stage retinal degeneration, particularly if this 
is made by a non-specialist.  Some forms of retinal degeneration, like retinitis 
pigmentosa, could be a part of a syndromic form of retinal degeneration like BBS.  By 
not taking into account the type of retinal degeneration until after the possible mutations 
have been identified, we eliminate the possibility of filtering out obviously pathogenic 




One cautionary finding from our study is that there were several patients that had areas of 
low coverage in genes of interest. One patient with Stargardt disease had a gap in 
coverage in ABCA4 that masked the pathogenic mutation.   Such gaps need to be filled in 
with Sanger sequencing.  A gap in coverage can complicate analysis if not detected as it 
would essentially show no mutation in the area with no or low coverage.  
We believe that all subjects should undergo appropriate psychophysical testing in order to 
refine the clinical diagnosis and then undergo a panel mutation screening for that 
diagnosis before being enrolled in a study for novel gene detection.  This should be 
followed by targeted exome sequencing of all genes linked to retinal degeneration.  In our 
study, 64% of the subjects were eliminated from further analysis after screening only 
genes linked to retinal degeneration.  Subjects with a recessive disease in which only 1 
pathogenic mutation is found (7% of the patients in this study, 20% of those without a 
genetic diagnosis) should be screened for CNVs and intronic variants in that gene.  After 
eliminating those with no relatives enrolled in the study, this would leave only 16% for a 
more in depth analysis using whole exome sequencing.   
The subjects with an unusually high mutational load merit further study as well.  We tend 
to view sporadic cases of early onset retinal degeneration as being due to an autosomal 
recessive mode of inheritance, or occasionally a de novo mutation.  Modifying alleles are 
sometimes identified which increase the severity of the disease phenotype, like the p. 
A229T variant in RPGRIP1L
24
.  However, the consequence of multiple heterozygous 
variants that can be pathogenic if there is a second mutation in the same gene has not 




high mutational load could help illuminate how many mutations can be tolerated.  
Studying the progression of retinal degeneration in these subjects can help show whether 
the additional mutations result in a more severe phenotype or have no obvious effect.   
Conclusion: 
Whole exome sequencing is a very effective approach for identifying novel mutations 
and narrowing down candidate genes for further analysis especially when paired with 
targeted analysis based on known retinal pathways.  If WES does not yield a molecular 
genetic diagnosis or a likely candidate for further analysis, whole genome sequencing can 
be used to identify non-coding (intronic) mutations.   While analysis of the parents and 
immediate family of the proband is not always required for identification of pathogenic 
variants, it does increase the likelihood of identifying pathogenic variants and could be 
needed if the mutations are not obviously pathogenic.   
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Supplement: 
Syndromic: 
Three siblings in one family were diagnosed with RP.  WES revealed two variants in 
BBS4 in the proband (Table 2-2; JB319).  The first mutation was a frameshift mutation 
likely resulting in nonsense mediated decay.  The second mutation was p.R295G.  While 
the arginine to glycine mutation is novel, an arginine to proline mutation at the same 
location has been previously reported to be pathogenic, making it very likely that the 
glycine substitution would be pathogenic as well
25
.  Mutations in BBS4 have been shown 
to cause Bardet-Biedl syndrome (BBS) but not non-syndromic retinitis pigmentosa.  
Segregation analysis confirmed that all three siblings were compound heterozygous for 
the BBS4 mutations and clinical analysis showed that their symptoms (retinitis 
pigmentosa, obesity and learning difficulties) were consistent with mild BBS. Renal 
dysfunction, polydactyly, and male hypogonadism are also commonly seen in Bardet-
Biedl syndrome but were absent in this family
26
.   
Another subject had Usher syndrome, a condition characterized by hearing loss and 
retinitis pigmentosa.  Clinical testing failed to reveal any known mutations leading to 
Usher syndrome.  WES revealed two novel frameshift mutations in GPR98 (Table 2-2; 
JB324), a gene known to cause Usher syndrome when mutated
27




Usher syndrome was found to have two mutations in USH2A (Table 2-2, JB252) that had 
been already classified as pathogenic.   
Stargardt, cone dystrophy and achromatopsia: 
Stargardt disease is a childhood onset macular degeneration and is most commonly 
caused by mutations in ABCA4.  Characteristic yellow flecks are typically seen under the 
macula during a fundus exam.  Five subjects presented with Stargardt disease and were 
found to have mutations in ABCA4 (Table 2-2: JB260, JB333, JB358, JB16, JB320).  Six 
of the mutations had been previously characterized and determined to be pathogenic 
while three novel frameshift mutations were found.   
Autosomal dominant Stargardt disease is caused by mutations in PROM1.  Interestingly, 
the dominant mutations seem to cause primarily cone degeneration while the recessive 
mutations can cause either rod or cone degeneration.  The dominant mutations in PROM1 
are typically gain of function missense mutations while the recessive mutations are loss 
of function mutations including frameshift mutations, splice site mutations and 
truncations.  Two loss of function variants were identified in patients with either 
Stargardt disease or cone dystrophy (see table 2-3; JB189, JB241).  A second variant was 
not identified in either case.  Since a dominant inheritance pattern was not established in 
these families, the pathogenicity of these variants is currently undetermined. 
One subject diagnosed with Stargardt disease was found to have a heterozygous 
p.V242M variant in CRX (Table 2-2; JB195).  This mutation is reported to be pathogenic 
and cause autosomal dominant cone rod dystrophy (CORD)
28




factor that is required for the development and maintenance of cone photoreceptors
29
.  
While many CRX mutations have been shown to reduce the ability of CRX to activate the 
rhodopsin promoter in vitro, the p.V242M mutation did not appear to affect the ability of 
CRX to activate the rhodopsin promoter, casting some doubt on the pathogenicity
30
.  It is 
possible that the p.V242M variant is pathogenic but has a different functional effect. The 
variant did not segregate with disease in the family in this study.  Both the mother and 
half-sister are heterozygous for the variant but do not have retinal degeneration.  It is 
possible that the p.V242M variant contributes to mutational load or digenic cause for 
disease, but based on the lack of segregation and lack of demonstrated functional effect, 
the variant is probably benign.   
Another subject presented with severe retinal degeneration that was classified as either 
achromatopsia or LCA (Table 2-2; JB301).  The proband had two novel mutations in 
GNAT2, a frameshift mutation and a missense mutation.  GNAT2 encodes the alpha 
subunit of cone transducing which is essential for phototransduction in cones
31
.  
Truncations are the most common pathogenic mutations in GNAT2, but pathogenic 
missense mutations in GNAT2 have been seen in both patients and mice
32,33
.  
Complicating the interpretation of the sequencing results for this subject, she had a 
p.A249E heterozygous mutation in GDF6 that has been reported to be autosomal 
dominant with incomplete penetrance
34-36
.  This variant has been reported to lead to LCA, 
microphthalmia and Klippel-Feil syndrome.  Notably, this subject does not have any 
skeletal defects that are sometimes reported to be associated with the p.A249E variant. 




the missense variant in GDF6.  Therefore, we determined that the GNAT2 mutations are 
the most likely genetic cause in this subject, with the GDF6 mutation potentially acting 
as a modifying allele and increasing the severity or playing no role in retinal degeneration 
in this subject.   
Another subject had an incoming diagnosis of LCA that was changed to cone dystrophy 
upon examination.  The diagnosis was further modified to achromatopsia after whole 
exome sequencing revealed two heterozygous mutations in CNGB3, one of which was 
novel (Table 2-2; JB426).   
LCA: 
LCA is a severe retinal degeneration which is symptomatic before the first year of age
37
.  
The retinal degeneration eventually includes cone loss as well.  It is one of the most 
severe forms of hereditary blindness.      In this study we found mutations in five different 
genes that resulted in LCA (see table 2-2).  Nine of the mutations (in ABCA4, CNGB3, 
KCNJ13, and PROM1) were novel.   
CEP290 mutations are the most common cause of LCA.  CEP290 is essential for cilia 
development and maintenance
38,39
.  Mutations in CEP290 cause many different 
ciliopathies including Joubert syndrome, Bardet-Biedl syndrome, Meckel syndrome and 
Senior-Loken syndrome
22,39
.  We found a novel splice site mutation in CEP290 in one 
patient with LCA (Table 2-2; JB165).  The second mutation was the deep intronic splice 
mutation
40
.  This case illustrates one of the limitations of WES for finding pathogenic 




CEP290 c.2991+1655A>G mutation is the most common mutation leading to LCA, the 
patient had been screened for it previously.  If the mutation had not already been 
identified and specifically looked for, we would not have identified the second mutation 
or been able to determine if the CEP290 splice site mutation was actually disease causing 
in this case or if the patient was simply a carrier for the mutation. 
Mutations in PRPH2 tend to be autosomal dominant due to haploinsufficiency
41
.  
Typically these mutations cause either retinitis pigmentosa or macular degeneration
42,43
.  
Homozygous or compound heterozygous mutations are much rarer and cause LCA or 
early onset RP when they do occur
44
.  The parents do not always have any functional 
vision loss but will usually show signs of mild retinal degeneration when examined.  One 
subject in this study was homozygous for a novel truncating mutation in PRPH2 (Table 
2-2; JB310).   
One subject was initially diagnosed with LCA.  WES revealed two mutations in PDE6A 
(Table 2-2; JB28) which has been shown to result in RP.  Upon re-evaluation the 
diagnosis was changed to early onset retinitis pigmentosa, which has a later age of onset 
and typically less severe progression.   
Retinitis Pigmentosa: 
Retinitis pigmentosa is a progressive form of retinal degeneration that primarily affects 
rod photoreceptors.  It has a later onset than LCA with a typical age of diagnosis of 35 
years old.  There is a wide range for the age of onset with some patients diagnosed during 
childhood and other being diagnosed in their 60s or even later
45,46




autosomal dominant or autosomal recessive.  Over 80 genes have been identified that can 
cause retinitis pigmentosa and the genetic cause is unknown in almost half of all patients 
diagnosed
47
.  In this study, 10 different genes were found to cause retinitis pigmentosa 
with two novel mutations (see table 2-2).  All of the genes have been previously shown to 
cause retinitis pigmentosa.   
Autosomal dominant RP (adRP) accounts for 15-40% of all cases of RP
3,48
.  So far, more 
than 20 genes have been identified that cause autosomal dominant RP
3,48
.  These include 
CA4, PRPH2 and PRPF31.  Dominant mutations tend to be pathogenic either due to 
heterozygous insufficiency or because they cause a toxic gain of function.  Mutations in 
all three of these genes seem to cause disease at least in part due to heterozygous 
insufficiency as a null allele is sufficient to cause disease.  The novel mutation we found 
in PRPH2 is an early stop codon so we did not follow up with functional testing.  The 
mutations in CA4 and PRPF31 are missense mutations that are near known pathogenic 
missense mutations in the genes.  CA4 mutations have been shown to impair the ability 
of the cells to regulate intracellular pH
49
.  The p.Q254P mutation in CA4 (Table 2-2; 
JB42) is very rare and currently classified as a variant with uncertain significance on 
dbSNP (rs150432787).  We were unable to perform a segregation analysis due to the lack 
of DNA from family members.  Interestingly, this patient was heterozygous for several 
mutations that are known to cause recessive forms of retinal degeneration including 
USH2A, ABCA4 and CDH23 as well as novel mutations in several other genes linked to 
retinal degeneration including BBS12, ROM1 and GPR98.  This is an unusually high 






Figure 2-1: Final outcome of initial screening for variants in genes associated with retinal 
degeneration.  Of the initial cohort of 69 subjects with retinal degeneration, the 
pathogenic variants were identified in 44 subjects, heterozygous mutations consistent 
with the diagnosis were identified in 5 subjects, 9 subjects had no obviously pathogenic 
variants and lacked relatives willing or able to enroll in the study to perform segregation 
analysis on potentially pathogenic variants. Eleven are good candidates for further 










unable to be performed




Incoming Clinical Diagnosis Number of 
patients 
adRP 5 
Cone dystrophy 3 
CORD 2 
LCA 24 










Table 2-1: Breakdown of diagnoses included in this study. adRP, autosomal dominant 
retinitis pigmentosa; LCA, Leber’s congenital amaurosis; CORD, cone rod dystrophy; 






Subject Dx gene Nucleotide change Protein change dbsnp citatio
n 
JB260 Stargardt ABCA4 c.6119G>A p.Arg2040Gln rs148460146 
50
 
c.2879del p.Ala960Aspfs*17 N/A   
JB333 Stargardt ABCA4 c.4363T>C p.Cys1455Arg rs758835368  
51
 
c.4666del p.Arg1556Glyfs*25 N/A   
JB358 Stargardt ABCA4 c.2588G>C p.Gly863Ala rs76157638 
52
 
c.3984_3987del p.His1328Glnfs*60  N/A  
JB16 Stargardt ABCA4 c.5917del p.Val1973*  rs61751389   
53
 
c.5917del p.Val1973* rs61751389   
53
 
JB320 Stargardt ABCA4 c.1749G>C p.Lys583Asn rs145265791   
51
 
c.4594G>A p.Asp1532Asn rs62642574 
54
 
JB249 LCA AIPL1 c.834G>A p.Trp278* rs62637014  
55
 
c.404_405insA p.Glu135fs*23  N/A  




c.883C>G p.Arg295Gly N/A   
JB42 adRP CA4 c.761A>C p.Gln254Pro rs150432787       
JB165 LCA  CEP290 c.2991+1655A>G splice mutation rs281865192     
40
 
c.3461+2TA>GT splice mutation N/A  
JB290 LCA CEP290 c.2390del p.Lys797Serfs*2 rs781670422     
56
 






CLN3 c.597C>A p.Tyr199* rs267606737 
57
 
c.597C>A p.Tyr199* rs267606737 
57
 
JB255 LCA (Batten 
Disease) 
CLN3 c.883G>A p.Glu295Lys rs121434286 
58
 
CNV suspected~    
JB426 CORD 
(Achromatopsia) 
CNGB3 c.1148del p.Thr383Ilefs*13 rs397515360    
59
 
c.1306A>C p.Ser436Arg rs748354081    
JB274 LCA CRB1 c.2300T>C p.Leu767Pro  N/A  
c.2300T>C p.Leu767Pro N/A  






c.1429G>A p.Gly477Arg rs866822473      
61
 
JB402 LCA CRB1 c.2843G>A p.Cys948Tyr  rs62645748    
62
 
c.3988G>T p.Glu1330* N/A  
JB38 RP FAM161A c.1355_1356del p.Thr452Serfs*3 rs397704718 
63
 
c.1355_1356del p.Thr452Serfs rs397704718 
63
 
JB301 LCA vs 
achromatopsia 
GNAT2 c.896C>A p.Ala299Glu N/A   
c.720+2T>C splice mutation N/A   
JB324 Usher's GPR98 c.14767del p.Thr4923Profs*8  rs747459491  
c.17668_17669del p.Met5890Valfs*10 rs757696771   
JB185 cone dystrophy 
(ad) 
GUCA1A c.296A>G p.Tyr99Cys rs104893967 
14
 






(p.Pro335_Ser336insSer in cis) 
 






c.3345C>G p.His1115Gln rs142032413 
20
 
JB32 RP NR2E3 c.119-2A>C splice mutation rs2723341 
65
 





NR2E3 c.767C>A p.Ala256Glu rs377257254 
67
 
c.119-2A>C splice mutation rs2723341 
65
 
JB48 RP (ad) NR2E3 c.166G>A p.Gly56Arg rs121912631 
68
 
JB275 LCA (ad retinal 
degeneration) 
OTX2 c.527del p.Pro177* N/A   
JB28 LCA (eoRP) PDE6A c.1705C>A p.Gln569Lys rs139444207 
69
 
c.1620+2T>A splice mutation     
JB33 adRP PRPF31 c.590T>C p.Leu197Pro N/A  
JB310 LCA PRPH2 c.522G>A p.Trp174* N/A   
c.522G>A p.Trp174* N/A   
JB167 ad retinal 
degeneration 
PRPH2 c.136C>T p.Arg46*  rs61755771      






JB284 LCA PROM1 c.2050C>T p.R684* rs530749007  
   c.2050C>T p.R684* rs530749007  
JB44 adRP RP1 c.2029C>T p.Arg677* rs104894082   
70
 
JB372 RP RP1L1 c.1138G>A p.Gly380Arg rs184332984     
71
 
c.1138G>A p.Gly380Arg rs184332984     
71
 
JB47 RP RP1L1 c.1270A>T p.Lys424* rs770463388       
c.1270A>T p.Lys424*  rs770463388       
JB283 LCA RPE65 c.1067_1068insA p.Asn356Lysfs*9   rs766074572  
c.1067_1068insA p.Asn356Lysfs*9   rs766074572  
JB357 LCA RPE65 c.1249G>C p.Glu417Gln rs62636299 
72
 
c.1102T>C p.Tyr368His rs62653011 
73
 
JB285 LCA RPGRIP1 c.767C>G p.Ser256* N/A   
c.1084_1087del p.Arg363Leufs*11 N/A   
JB124 LCA RPGRIP1 c.1180C>T p.Gln394*  N/A   




JB43 RP RPGRIP1L c.171G>T p.Leu57Phe  rs146925098  
c.628A>G p.Asn210Asp rs146584570  
JB41 RP USH2A c.1036A>C p.Asn346His rs369522997 
74
 
c.13335_13337del p.Glu4445_Asn4446delinsAsp rs775556188   
JB49 RP USH2A c.13297G>T p.Val4433Leu (benign?) rs111033381 
75
 
c.6713A>C p.Glu2238Ala rs41277212 
76,77
 
JB252 Usher's USH2A c.13207_13208del p.Gly4403Profs*15  rs746447649       
     
78
 




Table 2-2: Pathogenic and probable pathogenic variants in known disease causing genes identified in subjects in this study.  Only 
variants that completely explain the disease phenotype were included in this table.  LCA, Leber’s congenital Amaurosis; RP, retinitis 





subject DX gene Nucleotide change Protein change dbsnp citation 





JB188 Stargardt CNGB3 c.2139_2160del p.Lys714_Gln720del 
(p.Lys804*in cis) 
(rs151039691 in cis) 
59
 
JB23 LCA KCNJ13 c.458C>T p.Thr153Ile rs863224884  
JB189 Stargardt PROM1 c.303+1G>A splice mutation rs777673930      
JB241 cone dystrophy PROM1 c.1623_1624del p.Y541fs N/A   
Table 2-3: Heterozygous variants identified in subjects with recessive disease.  The variant is most likely pathogenic and is consistent 
with the diagnosis but we were unable to identify the second mutation.  These subjects should be screened for copy number variants 





subject DX Disease 
causing gene 
Other genes Nucleotide 
change 
Protein change dbsnp citation 
JB333 Stargardt ABCA4 IQCB1 c.772delA p.Arg258Aspfs*4 N/A  
JB320 Stargardt ABCA4 RD3 c.16T>C p.Trp6Arg rs35649846 
80
 
c.69G>C p.Glu23Asp rs34422496 
80
  
JB9 Retinal degeneration 
(Batten Disease) 





JB375 RP CRB1 AHI1 c.653A>G  p.Tyr218Cys  rs183936286       
82,83
  
c.3257A>G p.Glu1086Gly rs148000791 
82,84
 
JB38 RP FAM161A RPGRIP1L  c.685G>A p.Ala229Thr rs61747071 
24
 
JB301 LCA vs achromatopsia GNAT2 GDF6  c.746C>A p.Ala249Glu rs121909352 
36
 
JB32 RP NR2E3 USH2A c.2137G>C p.Gly713Arg rs696723 
85
 





NR2E3 ABCA4 c.2828G>A p.Arg943Gln rs61749446 
54,87
 







JB48 RP (ad) NR2E3 USH2A c.10246T>G p.Cys3416Gly rs527236140 
86
 
c.14419G>A p.Ala4807Thr rs534656527  
JB275 LCA (ad retinal 
degeneration)  
OTX2 RP1 c.5673G>T p.Leu1891Phe rs139088785 
  
  
JB28 LCA (eoRP) PDE6A IQCB1 c.962T>A p.Val321Glu  N/A   
JB284 LCA RD3  USH2A c.10451G>A p.Arg3484Gln  rs771999994 
76
 
c.13709G>A p.Arg4570His rs730254 
76
 





JB49 RP USH2A RP1 c.4875A>G p.Ile1625Met rs757644601  
JB195 Stargardt  unknown
  
CRX c.724G>A p.Val242Met  rs61748459 
28
 
JB42 adRP CA4 ABCA4 c.1140T>A p.Asn380Lys rs61748549    
90
 
BBS12 c.617T>G p.Val206Gly N/A  






    
GPR98 c.6017G>A p.Gly2006Asp rs768201036 
   
 
USH2A c.2276G>T p.Cys759Phe rs80338902  
85
 
JB307 Cone dystrophy KIF7 BBS1 c.1169T>G p.Met390Arg rs113624356 
92
 
CEP164 c.4228C>T p.Gln1410* rs147398904  
RPGRIP1 c.1639G>T p.Ala547Ser rs10151259 
93
 
CLN3 c.1189G>A p.Ala397Thr rs754468227 
        
 
RP1l1 c.6359A>G p.Glu2120Gly N/A  
JB284 LCA (RP) PROM1 USH2A c.13709G>A p.Arg4570His rs730254 
76
 
USH2A c.13297G>T p.Val4433Leu rs111033381 
75
 
USH2A c.10451G>A p.Arg3484Gln  rs771999994 
    
 
RP1 c.5840T>G p.Leu1947Trp N/A  






BBS1 c.700G>A p.Glu234Lys rs35520756 
95
 
ABCA4 c.3602G>T p.Leu1201Arg rs61750126 
54
 
RD3 c.69G>C p.Glu23Asp rs34422496 
80
 
RD3 c.16T>C p.Trp6Arg rs35649846 
80
 
WFS1 c.862G>A p.Val288Met rs71537685  
WFS1 c.1949A>G p.Tyr650Cys N/A  
WFS1 c.2008G>A p.Gly670Ser N/A  
JB274 LCA CRB1 KIF7 c.A2501A>G p.Gln834Arg rs138354681 
20
 
BBS1 c.1396G>A p.Ala466Thr N/A  
FAM161A c.1133T>G p.Leu378Arg rs187695569 
     
96
 
MAK c.112A>C p.Lys38Gln N/A  
RGS9 c.1351C>A p.Gln451Lys N/A  
 
Table 2-4: Additional heterozygous variants of uncertain significance found in this study.  These variants are unlikely to be pathogenic 




RP, retinitis pigmentosa; BBS, Bardet Biedl Syndrome; CORD, cone-rod dystrophy; eoRP (early onset RP).  Homozygous mutations 





subject DX Disease 
causing gene 
Other genes Nucleotide 
change 
Protein change dbsnp Citation 
JB40 Multiplex 
RP 
unknown RPGRIP1L c.685G>A p.Ala229Thr rs61747071 
24
 
RPGRIP1L c.2952G>C p.Gln984His rs775144757    
RPGRIP1L c.196C>A p.Gln66Lys rs751444506      
CDH23 c.1096G>A p.Ala366Thr rs143282422 
91
 
CDH23 c.3293A>G p.Asn1098Ser rs41281310 
97
 
FAM161A c.977A>C p.Lys326Thr rs745318331    
GUCY2D c.3247C>A p.Leu1083Met N/A  
USH2A c.6713A>C p.Glu2238Ala rs41277212 
77
 




Table 2-5: Multiple compound heterozygous mutations were identified in a subject with multiplex retinitis pigmentosa.  This family 
appears to have an unusually high number of recessive mutations rather than the single dominant mutation that was expected based on 
the family history.  We were unable to perform segregation analysis.  The CDH23 mutations and RPGRIP1L mutations are the most 
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Background: Variants in PRPF31, which encodes pre-mRNA processing factor 31 
homolog, are known to cause autosomal dominant retinitis pigmentosa with incomplete 
penetrance. However, the majority of mutations cause null alleles, with only two proven 
pathogenic missense mutations.   We identified a novel missense mutation in PRPF31 in 
a family with ADRP.   
Methods: We performed whole exome sequencing to identify possible pathogenic 
mutations in the proband of a family with ADRP.  We carried out segregation analysis of 
the probable mutation, PRPF13 c.590T>C.  We evaluated the cellular localization of the 
PRPF31 variant (p.Leu197Pro) compared to the wildtype PRPF31 protein. 
Results:  PRPF31 c.590T>C  does segregate with disease in this family.  One family 
member has the mutation but is unaffected, which is consistent with previous reports the 
incomplete penetrance of PRPF31 mutations.  Unlike the wildtype PRPF31 protein, the 
mutant PRPF31 protein (p.Leu197Pro) does not localize to the nucleus. Instead, it 
localizes primarily to vesicles in the cytoplasm. 
Conclusions:  c.590T>C is a novel pathogenic variant in PRPF31 causing autosomal 
dominant retinitis pigmentosa with incomplete penetrance likely due to protein 







Retinitis pigmentosa (RP) is the most common form of inherited retinal degeneration, 
affecting 1 in 2500-7000 people
1
.  Over 60 genes have been shown to cause RP
2
.  It can 
be inherited in an autosomal recessive, autosomal dominant or x-linked inheritance 
pattern, with different genes associated with each inheritance pattern
3
.  Approximately 
30-40% of the cases of retinitis pigmentosa are autosomal dominant
3
.  Dominant disease 
can be due to either a toxic gain of function in which the mutation causes the protein to 
have a directly toxic effect on the cell or haploinsufficiency, where half the normal 
amount of protein is insufficient to fulfill the needs of the cell.   
PRPF31 encodes a ubiquitously expressed splicing factor
4
.  It links the U4/U6 complex 
with U5, creating the tri-snRNP of the spliceosome
5
.  PRPF31 mutations are known to 
cause autosomal dominant RP with incomplete penetrance (RP11, OMIM 600138)
4,6-11
.  
It is interesting that PRPF31 mutations result in a retina specific phenotype when the 
splicing factor is ubiquitously expressed.  A retina specific isoform has not been 
identified that can explain the tissue specific susceptibility of the retina to a heterozygous 
mutation in PRPF31
12
.  The retina appears to simply have a higher dependence on this 
splicing factor than other tissues.  Deery et al speculated this could be due to the need to 
constantly replenish disc proteins in the outer segments, resulting in a higher splicing 
load than in other cell types
13
.  It is also possible that there are splicing factors in other 





The incomplete penetrance seen in families with PRPF31 mutations is due to the variable 
expression levels of PRPF31
9,10
.  There is a critical level of PRPF31 needed to avoid 
retinal degeneration.  If both alleles are wildtype, the critical level is exceeded and retinal 
degeneration is avoided.  However, if the expression level of one wildtype allele is high 
enough, a carrier of a pathogenic allele will still reach the critical level of wildtype 
protein and be asymptomatic.  If the wildtype allele has an average or low level of 
expression, a carrier of a pathogenic allele will develop retinal degeneration.   
We identified a novel missense mutation in PRPF31.  Most mutation in PRPF31 are 
truncations, deletions or frameshift mutations which result in a null allele
14
.  However, 
two missense mutations have been shown to be pathogenic and are located within 20 
amino acids of the novel mutation seen in the family in this study, suggesting it could be 
in an important domain for protein function.  We analyzed the segregation of the 
mutation within the family and the impact of the mutation on localization of the protein 
and concluded that it was the disease causing mutation in this family. 
Methods: 
Whole Exome Sequencing:  Testing was carried out samples from human subjects after 
obtaining written informed consent on an Institutional Review Board (IRB) approved 
protocol (#808828). A sample from the proband was screened previously for mutations in 
rhodopsin, peripherin/RDS and ROM1 (Carver Lab, University of Iowa, Iowa City, IA, 
1995) and found to be negative. For whole exome sequencing, we performed target 




sequencing was performed on Illumina HiSeq2000 at the Penn Genome Frontiers 
Institute (PGFI).  We used Galaxy to analyze the whole exome sequencing data set
15
.  
The FASTQ files were aligned to hg18 using BWA for Ilumina (Burrow-Wheeler 
Aligner).  Variants were identified with Freebayes and the variants were annotated using 
Annovar
16,17
.  We then filtered the variants to include only those in genes linked to retinal 
degeneration that had an allele frequency of 0.05 or less.  This yielded a short list of 
genes which were prioritized based on mutation type and likelihood to cause autosomal 
dominant retinitis pigmentosa.  The PRPF31 variant was the strongest candidate.     
Segregation Analysis:  We used PCR to amplify the DNA region that included the variant 
from the proband and all relatives who provided DNA using Phusion (New England 
Biolabs, Ipswich, MA) and the following primers synthesized by Invitrogen (Carlsbad, 
CA): GAGCCTTCCTGAGTTCCCG and  GCCAAAGCCCCCATTCTAC.  The PCR 
product was sent for sanger sequencing at the Penn Genomics Analysis Core and 
visualized using SnapGene software (from GSL Biotech (Chicago, IL); available at 
snapgene.com).   
Cloning:  We cloned the sequences for PRPF31 from a cDNA library generated from 
293T cells.  We used Q5 polymerase (New England Biolabs) and custom primers 
synthesized by Invitrogen.  The PCR product was TOPO cloned and the sequences were 
verified by Sanger sequencing at the Penn Genomics Analysis Core.  The coding 
sequences were cloned into an expression vector with an HA tag using In-Fusion (Takara 





Mutagenesis:  We used site directed mutagenesis (QuikChange II Site-Directed 
Mutagenesis Kit from Agilent Technologies; Santa Clara, CA) to introduce the p.L197P 
variant into the cloned PRPF31 using the following primers: 
GATGCGGTGCTTGGAGGCGTTCGGCTCCAGCGCCATGTCGCAG and 
CTGCGACATGGCGCTGGAGCCGAACGCCTCCAAGCACCGCATC.   
Transfection:  ARPE19 cells were maintained in DMEM F12 media (Invitrogen) 
supplemented with 10% fetal bovine serum.  We plated the cells in 4 well chamber slides.  
The cells were transfected using Lipofectamine LTX with plus reagent (Thermo Fisher 
Scientific; Agawam, MA) and fixed 48 hours post-transfection. 
Immunofluorescent staining:  The ARPE19 cells were fixed for 15 minutes in 4% 
paraformaldehyde.  They were rinsed three times with Dulbecco’s phosphase-buffered 
saline (Corning 21-030-CV).  We then blocked the cells for one hour using a blocking 
buffer consisting of 10% normal goat serum and 0.5% Triton X-100 in PBS.  The slides 
were then incubated overnight at 4 degrees with an antibody against the HA tag (Cell 
Signaling Technology #3724; Danvers, MA) at a 1:800 dilution. The slides were then 
incubated at room temperature for 3 hours in Alexafluor 488 Goat anti-Rabbit 
(ThermoFisher Scientific A-11034).  The cells were mounted using Fluoromount-G 
mounting media contained 4',6-Diamidino-2-Phenylindole (DAPI).   The cells were 
imaged using an Olympus FV1000 confocal microscope with a 60X oil immersion 






A 37 yo woman presented with worsening vision and light sensitivity over the preceding 
5 years. Previous electroretinogram (ERG) testing had shown near normal cone responses 
with severe rod B wave amplitude loss. Her brother had also complained of worsening 
vision. Clinical examination showed visual acuity of 20/25 in the right eye and 20/30 in 
the left eye. The retinal examination showed marked vessel attenuation, waxy pallor of 
the optic disc, and relatively symmetrical mid-peripheral pigment epithelial atrophy 
(Figure 3-1A). There were neither bone spicules nor vitreous debris typical of retinitis 
pigmentosa. Visual field testing showed an equatorial scotoma in the temporal retinas of 
both eyes (Figure 3-1B). The family history was consistent with an autosomal dominant 
pattern of inheritance with incomplete penetrance (see Figure 3-1C).  To her memory, her 
father had not received a diagnosis with any form of retinal degeneration.  Two of her 
brothers had been diagnosed with retinitis pigmentosa (Figure 3-1C).  None of the 
proband’s children (current ages 26, 30 and 32) have been diagnosed with retinal 
degeneration.   
Analysis of the whole exome sequencing data shows that the proband has a novel 
c.590T>C (p.Leu197Pro) missense variant in PRPF31 (Figure 3-1D).  This variant is not 
listed in dbSNP or ExAC.  Two missense mutations in PRPF31 that are known to be 
pathogenic are p.Ala194Glu and p.Ala216Pro. The proximity of the new variant with 
these other amino acid changes suggests that this region is an important domain for 
protein function
11
.  Since PRPF31 is a splicing factor, mislocalization from the nucleus 




p.Leu197Pro variants are located in the second coiled coil domain while the p.Ala216Pro 
links the coiled coil to the Nop domain which is a ribonuclearprotein (RNP) recognition 
motif
18
.   
Three of the proband’s siblings (one affected, two unaffected) were tested for the 
c.590T>C mutation in PRPF31 (see figure 3-1C).  One affected brother was 
heterozygous for the variant while two of the unaffected siblings were homozygous for 
the wildtype allele.  One of the unaffected siblings (sister, II-4) is a carrier for the 
c.590T>C variant.  In sum, the inheritance pattern is consistent with AD disease with 
incomplete penetrance typically seen in PRPF31 mutations.  Although the asymptomatic 
carrier may continue to enjoy good vision, any children that she may have who inherit the 
mutation will be at risk for retinal degeneration. 
Since the previously known PRPF31 missense variant proteins mislocalize to the 
cytoplasm
13
, we tested the cellular localization of the p.Leu197Pro variant.  We cloned 
the cDNA sequence for PRPF31 from 293t cells and verified that it matched the reference 
sequence.  We then performed site directed mutagenesis to add the c.590T>C variant.  




 into expression vectors, each with driven by 
a constitutive promoter (the chicken b actin promoter and cytomegalovirus enhancer 
(CMV/CBA)) and the transgene was tagged with the human influenza hemagglutinin 
(HA) marker.  We transfected ARPE19 cells and analyzed protein localization 48 hours 
post transfection with confocal microscopy.  PRPF31
WT
 localized almost exclusively to 
the nucleus with a small amount of protein seen in the cytoplasm in cells with particularly 
high expression (Figure 3-2).  In contrast, the PRPF31
L197P




staining pattern in the cytoplasm, possibly indicating that it is being targeted for 
degradation.   
Discussion: 
Mutations in PRPF31 are well known to cause ADRP with incomplete penetrance.  Most 
of these mutations are truncations, frameshifts, splicing mutations or large deletions, all 
of which cause null alleles.  Pathogenic missense mutations in PRPF31 are much rarer.  
The universal protein resource site (uniprot.org) only lists two missense mutations 
associated with RP11.  The single nucleotide polymorphism database (DbSNP) only 
classifies two missense variants in PRPF31 as “pathogenic”, while listing three more as 
“likely pathogenic”.  Given that the RP11 phenotype involves incomplete penetrance and 
pathogenic missense variants are rare, functional testing is more important than usual to 
establish pathogenicity.  The fact that the variant PRPF31 is not localized to the nucleus 
makes it impossible for PRPF31
L197P 
to be functional as a splicing factor. 
The mislocalization seen in the PRPH31 p.Leu197Pro protein variant as well as the 
previously described p.Ala194Glu and p.Ala216Pro variants is interesting considering 
they are unlikely to disrupt a nuclear localization signal.  Ala194 and Leu197 are located 
in a coiled coil domain while Ala216 is in a linker region between the coiled coil and the 
NOP domain
18
.  It seems likely that these missense mutations are destabilizing the protein 
structure or disrupting protein folding and causing the protein to be targeted for 
degradation.  This is consistent with the staining pattern we observed for PRPF31
L197P






 We conclude that the c.590T>C missense variant in PRPF31 is a pathogenic mutation 
causing autosomal dominant retinitis pigmentosa with incomplete penetrance.  The 
phenotype is consistent with the phenotype seen from other PRPF31 mutations, the 
mutation segregates with disease in the family with incomplete penetrance, and the 
missense mutation causes mislocalization of the protein in vitro.   
Acknowledgements: We thank the subjects for their participation in this project. 
Funding: This study was funded by a Center grant from Foundation Fighting Blindness to 
the CHOP-Penn Pediatric Center for Retinal Degenerations, the Brenda and Matthew 
Shapiro Stewardship and the Robert and Susan Heidenberg Investigative Research Fund 
for Ocular Gene Therapy, Research to Prevent Blindness, the Paul and Evanina Mackall 
Foundation Trust, NIH Vision Training Grant 5T32EY007035-37, the Center for 







Figure 3-1: Clinical features and molecular data for PRPF31 family.  A) Fundus photos 




pallor of the optic disc, and relatively symmetrical mid-peripheral pigment epithelial 
atrophy. OD, right eye (ocula dextra); OS, left eye (ocula sinestra); B) Visual field testing 
results of the proband. There are bilateral equatorial scotomas in the temporal retinas; C) 
Pedigree for the family, which has affected members in three generations, both male and 
female.  The father of the proband was apparently unaffected, indicating incomplete 
penetrance.  DNA samples were obtained from the numbered family members.  The 
proband is indicated with an arrow; D) .Sanger sequencing results for the PRPF31 
c.590T>C variant.  The variant was confirmed in the proband (II-2) and the affected 
brother (II-1).  One of the unaffected sisters (II-4) is homozygous for the wildtype allele 










in ARPE19 cells as measured by 
immunofluorescence for the HA tag (green). Nuclei appear blue due to staining with 4',6-
Diamidino-2-Phenylindole (DAPI). PRPF31
L197P 
mislocalized to the cytoplasm while 
PRPF31
WT
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 Three different missense variants in SEMA4A have been identified in retinitis 
pigmentosa (RP) patients and presumed to be pathogenic: p.R354H, p.F350C and 
p.R713Q
1
.  p.R354H and p.F330C were reported to be recessive mutations while 
p.R713Q was reported to be a dominant mutation.  The variants were classified as 
pathogenic since: 1) they segregated with the disease in the respective families, and 2) 
they were not found in 100 ethnically matched normal-sighted control individuals
1
.  Here 
we review laboratory results relating to SEMA4A variants and present data that contradict 
previous conclusions that particular SEMA4A variants are pathogenic. 
Nogima et al created knock-in mouse lines for SemA4a missense variant
2
.  Of the 
three variants, only the p.F350C variant resulted in retinal degeneration in mice
2
.  As the 
authors mention, it is possible that the difference in SEMA4A sequence between human 
and mouse can account for the differences in the effects of the variants between these two 
species.  However, it is also possible that the variant is not pathogenic and is merely a 
benign polymorphism or a risk factor for blindness that is not sufficient to cause disease 
on its own.  Additional studies in the ARPE19 human retinal pigmented epithelium 
(RPE) cell line demonstrated that the p.D345H and p.F350C variants do not properly 
localize to the cell membrane and also cause deficits in phagocytosis or ER stress 
response to oxidative stress
3
.  Conversely, the p.R713Q variant did not affect 
phagocytosis, ER stress response or protein localization
3
. 
 After obtaining consent and collecting blood samples for DNA (UPenn IRB 
#808828), we analyzed whole exome sequencing data from patients with genetic forms of 
retinal degeneration seen at the Scheie Eye Institute Department of Ophthalmology.  We 




p.R713Q variant of SEMA4A.  Further analyses showed that the variant did not segregate 
with the disease in any of the families.  The details are as follows:  
Family A: This family has autosomal dominant retinal degeneration which is manifest as 
retinitis pigmentosa in some individuals (II-2) and macular dystrophy in others (II-4, III-
1, II-1). The p.R46X mutation in PRPH2, known to be pathogenic, segregates with the 
disease. The proband is a 74 year old woman with macular dystrophy (II-4, Figure 4-1A) 
who has been followed for the past 39 years.  While most of the relatives tested had 
retinal degeneration and were heterozygous for the p.R713Q variant in SEMA4A, the 
brother of the proband, II-7, was heterozygous for the SEMA4A variant (but not the 
PRPH2 mutation) and had no symptoms or signs of retinal/macular degeneration.  
Family B: A 43yo female (proband II-2, Figure 4-1B) presented with unilateral 
pigmentary retinal degeneration. She had been symptomatic since age 19. Examination 
was notable for marked asymmetry, with bone spicules and peripheral to central retinal 
degeneration in the right eye only and asymmetric ERGs and visual fields.  Over the next 
14 years, lattice degenerative changes commenced in the left eye.  Neither parent had a 
history of retinal disease.  The proband II-2 was diagnosed with simplex RP.  Neither the 
30yo son nor the 32yo daughter of the proband shows signs of retinal disease. The 
proband is homozygous for the p.R713Q variant of SEMA4A.  The son (III-1) and the 
daughter (III-2) are heterozygous for the p.R713Q variant of SEMA4A .  Based on the 
pedigree of this family, it would be possible for the p.R713Q variant of SEMA4A to cause 
AR disease, but it is not consistent with a dominant mutation.  We were unable to 
positively identify the pathogenic mutation(s) in this proband after exploring numerous 




HOXD1, DLEC1, ALS2CL, COL4A1, MRPS31, and STARD8).  We suspect that either a 
novel gene is responsible or a de novo mutation arose in the one affected retina. 
Family C:  An otherwise healthy 67yo male (proband II-3, Figure 4-1C) presented with 
light perception only vision.  An ophthalmic exam revealed widespread pigmentary 
changes, retinal thinning and vessel attenuation.  He had been diagnosed with simplex RP 
in his 20’s.  His sisters and brothers and two sons (each in their 30’s) had normal vision. 
Genetic testing revealed that the proband is heterozygous for the p.R713Q variant in 
SEMA4A.  Three of his unaffected siblings are also heterozygous for the variant.  
Additionally, his unaffected 43yo son is homozygous for the p.R713Q variant of 
SEMA4A.  The fact that an unaffected family member is homozygous for the mutation 
indicates that this mutation is insufficient to cause disease.  The pathogenic mutations in 
this family is likely to be in USH2A as the proband has compound heterozygous 
mutations in USH2A (p.R4192H and p.R1653*) and no other family member has 
mutations in both alleles. 
In summary, we describe three families with retinal degeneration and in which the 
SEMA4A p.R713Q variant was observed in both affected and unaffected individuals. Our 
findings are inconsistent with the dominant pattern of inheritance currently ascribed to 
the SEM4A p.R713Q variant
1
. Not only is there a lack of segregation of the mutation with 
disease, but also one of the unaffected family members in family C is homozygous for the 
variant, thus eliminating the possibility that the variant leads to a recessive disease.  
These results are consistent with the results from the mouse model generated by Nogima 
et al that was homozygous for the p.R713Q missense Sema4a variant.  This mouse did 
not show any signs of retinal degeneration.
2,3




Sema4a change could lead to disease when combined with a mutation in another gene, 
but it is not sufficient to cause disease in isolation.   
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Figure 4-1: Family Pedigrees and clinical findings.  Three families carry the p.R713Q 
missense variant in SEMA4A (c.2138G>A).  A) Family A has a dominant inheritance 
pattern with multiple affected individuals.  B) Family B has one affected member with 
autosomal recessive retinitis pigmentosa.  C) Family C has one affected member with 
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Introduction: 
According to the WHO, 39 million people worldwide are totally blind 
(http://www.who.int/mediacentre/factsheets/fs282/en/). For these patients, very limited or 
no treatment options exist. In many cases, the underlying causes of retinal blindness are 
genetic. Gene replacement and gene knockdown strategies aiming to restore vision are 
being tested and move toward clinical trials for such individuals, but these therapies will 
only work if the retinal neurons are still present in the patient. Additionally, it would be 
prohibitively expensive to develop a gene augmentation therapy for each of the >200 
different genes that contribute to blinding retinal diseases, some of which have only been 
identified in a handful of patients worldwide.  For many of the advanced stages of retinal 
degeneration, there are no available treatments or therapies. In these patients, most of the 
photoreceptor cells (rods and cones) – the light sensors of the eye, are degenerated and/or 
lost.   
Recently, optogenetic strategies to restore light sensitivity to the remaining cells of the 
retina (photoreceptors, bipolar cells or ganglion cells) have seen considerable success in 
mice
1-4




cells to make them responsive to light. In severe retinal degeneration, targeting these light 
sensors to retinal cells will create artificial photoreceptors and stimulate the remaining 
retinal circuitry to function. There are a few different ways by which retinal activity can 
be restored in the non-functioning retina using optogenetics, but based on what is most 
well understood, three different strategies have been used in animal models
5
. In one 
strategy, Busskamp et al. genetically targeted a light sensitive chloride channel - 
enhanced Natronomonas pharaonis halorhodopsin (eNpHR), which hyperpolarizes in the 
presence of light, to the photoreceptors present in blind mice and reported restoration of 
visual responses and visually guided behavior
1
. In a second strategy, Lagali et al. targeted 
a different light sensor that depolarizes in the presence of light – channelrhodopsin-2 
(ChR2) to the ON-bipolar cells of blind mice using an ON bipolar cell (BC) specific 
promoter
6
. These mice demonstrated an improvement in visually guided behavior and 
locomotion indicating a restoration of visual function. Engineering of the ChR2 gene 
gave rise to a modified version called CatCh with increased sensitivity to light and faster 
channel kinetics
7
.. Another strategy is to target the retinal ganglion cell.  Bi et al targeted 
CHR2 by using a ubiquitous promoter and administering via subretinal injection.  While 
this strategy does result in in ganglion cell responses, it eliminates all retinal processing 
and activates both ON and OFF pathways simultaneously
8
. 
ON bipolar cells are particularly attractive targets because they would theoretically retain 
the most retinal signal processing after photoreceptor cell death.  In order to effectively 
target the ON bipolar cells without also expressing the optogenetic protein in the OFF 




used as a cell specific promoter
2,3
.  It is expressed in both the ON cone bipolar cells and 
the rod bipolar cells (which are also ON bipolar cells).  Since mGluR6, the protein 
product of GRM6, is involved in the signal inversion necessary for the ON pathway, it is 
not expressed in the OFF bipolar cells.   
The 9.5 kb mGRM6 promoter was identified by Ueda et al. and used to create a 
transgenic mouse line with β-galactosidase expression in the retina restricted to ON 
bipolar cells
9
.  While the expression profile was very specific, the promotor was too large 
for AAV, which is currently the viral vector of choice for gene therapy targeting neural 
retina.  An essential 200bp enhancer sequence was identified within the full promoter that 
conveys bipolar cell specific expression when paired with the ubiquitous SV40 promoter 
in the wildtype mouse retina
10
.  Adding additional copies of the enhancer increased 
expression levels and specificity, with four copies achieving the optimal expression 
(referred to as the 4xGRM6-SV40 promoter) 
3
.   
Early studies have shown that 4xGRM6-SV40 promoter can be used to drive 
channelrhodopsin expression in ON bipolar cells.  They showed specific expression in 
the ON bipolar cells of the treated wildtype (WT) mice and behavioral improvement in 
rd1 mice with retinal degeneration
2,3,11
.  However, a recent study found that bipolar cell 
specific expression was not observed using the 4xGRM6-SV40 promoter in rd1 mice
12
.   
We used the 4xGRM6-SV40 promoter and the TRPM1 promoter to drive eGFP 
expression in the ON-bipolar cells of mice with retinal degeneration to test the specificity 




expression in bipolar cells, ganglion and amacrine cells.  Surprisingly, we occasionally 
saw expression in the retinal pigmented epithelium (RPE).  The TRPM1 promoter also 
failed to provide ON bipolar cell specific expression in mice with retinal degeneration 
whereas it drove high levels of ON bipolar expression in mice with wildtype retinas.  
This dramatic change in expression profile suggests that retinal degeneration has a more 
profound effect on gene expression than previously suggested and that optogenetic 
therapy for late stage retinal degeneration may be better targeted to ganglion cells to 
bypass all retinal processing.   
Methods: 
Expression constructs: The 4xGRM6-SV40-CatCh-eGFP construct was a kind gift from 
Dr. Botond Roska.  It was packaged it in AAV7m8 and AAV8BP2 at the Center for 
Cellular and Molecular Therapeutics at the Children’s Hospital of Philadelphia.  For later 
experiments, we removed the coding sequence for CatCh and used only 4xGRM6-SV40-
eGFP and that was packaged in AAV8BP2 and AAV7m8 at the CAROT Research 
Vector Core.  The human TRPM1 promoter was cloned from human genomic DNA by 
PCR amplification (forward primer acgcgtagccactcaccagac; reverse primer 
ggatccctcctgagtttgtccac) and inserted in front of the CatCh-eGFP transgene.   The 
TRPM1 vectors were packaged into AAV7m8 and AAV8BP2 at the Centre for advanced 
retinal and ocular therapeutics (CAROT). 











) from Jackson laboratory and maintained them 
under a 12 hour light dark cycle (see table 5-1 for details on mouse lines).  Mice were 
injected with ~ 3 uL of virus either subretinally or intravitreally under isofluorane 
anesthesia as previously described
13
.  Both AAV7m9-4xGRM6-SV40-CatCh-eGFP and 
AAV8BP2-4xGRM6-SV40-CatCh-eGFP were injected at a titer of 1E+13vg/ml and 
AAV8b-4xGRM6-SV40-eGFP was injected at a titer of 9.48E+12vg/ml. The rd1 mice 
were injected at 1 month and 8 months of age.  Rd16 and rd10 mice were treated at 5 
months of age at the LCA5 mice were treated at 6 months.  Eyes were harvested 4-8 
weeks post injection and fixed in 4% paraformaldehyde for 20 minutes.  The eyes were 
frozen and cryosectioned. For the TRPM1 studies, mice were injected with ~3ul 
subretinally (AAV8BP2) or intravitreally (AAV7m8) – TRPM1-CatCh-eGFP at a titer of 
8.19E+12vg/ml.  Wildtype mice were injected at 1 month of age and eyes were harvested 
one month post injection. Rd1 mice were injected at 4 weeks of age and eyes were 
harvested at 4 months post injection.  
Retinal explant cultures: Retinas were isolated from a 5 year old Crd1 dog with advanced 
retinal degeneration post euthanasia and cultured as described previously (Cronin et al.) 
for 12 days. They were then mounted on slides and imaged using the Olympus FV1000 
confocal microscope with a 40X oil immersion objective. 
Immunohistochemistry: The retinal sections were blocked with a blocking buffer 
consisting of 10% normal goat serum and 0.5% Triton X-100 in Phosphate Buffered 
Saline (PBS).  We incubated the slides overnight with a rabbit anti-GFP antibody 




three hours at room temperature with Alexafluor 488 Goat anti-Rabbit (ThermoFisher 
Scientific #A-11034).  We mounted the coverslips using Fluoromount-G mounting media 
contained DAPI.  We imaged the slides using an Olympus FV1000 confocal microscope 
with a 40X and 60X oil immersion objective or with a Zeiss fluorescent microscope.   
Results: 
To compare transduction efficiency of the 4XGRM6-SV40 promoter in bipolar cells of 
healthy and degenerating retinas, we used two different AAV serotypes- AAV7m8 and 
AAV8BP2.  AAV8BP2 has been shown to target the bipolar cells efficiently in wildtype 
mouse retinas and to elicit ganglion cell responses in the rd1 mice (Cronin et al).  
AAV7m8 can also target the bipolar cells by subretinal and intravitreal routes of injection 
and has been used to target ChR2 to the ON-bipolar cells for optogenetic therapy in an 
RP mouse model
11
.  In this study, we administered AAV8BP2 or AAV7m8 containing 
the 4xGRM6-SV40-CatCh-eGFP transgene cassette by subretinal injection in wildtype 
(WT) and rd1 mice at P90. While CatCh-eGFP expression in the wildtype mouse retinas 
was robust and restricted mostly to the ON bipolar cells, expression in the rd1 mice was 
poor and not bipolar cell specific. Rather, CatCh-eGFP expression seemed to be primarily 
in amacrine and ganglion cells (Figure 1).  Furthermore, no improvement in visually 
guided behavior (water maze) was observed compared to untreated rd1 mice (data not 
shown). 
We wondered whether the misexpression of 4x GRM6-SV40 promoter in the rd1 mice 




was due to the ectopic expression of CatCh.  To eliminate these confounding factors we 
performed further expression studies using the 4x GRM6-SV40 promoter driving eGFP 
expression without CatCh.  We injected 1 month old and 8 month old rd1 mice with 
AAV8BP2- 4xGRM6-SV40-eGFP by subretinal injection and harvested the eyes 6 weeks 
later.  Both the young and old rd1 mice showed non-specific eGFP expression in 
ganglion cells, muller glia cells and amacrine cells, but the younger mice did show a 
higher level of expression in more bipolar cells than was seen in the older mice (Figure 
2). Although we saw more specific eGFP expression in the younger rd1 mice, expression 
in the injected region was patchy, with some areas of the retina showing exclusively 
bipolar cell specific expression (Figure 3a-d), other areas having bipolar cell and non-
specific expression (Figure 3e-h and figure 3i-l), and still others showing no bipolar cell 
expression at all but expression in a few amacrine or ganglion cells (Figure 3m-p).  
Islands of remnant cone cell bodies seemed to be associated with areas where the 
expression was exclusively in bipolar cells, suggesting that the loss of specificity is a 
result of progressing degeneration. We also occasionally observed eGFP expression in 
the RPE cells (data not shown).   
Rd1 mice are a fast degenerating mouse model of retinitis pigmentosa where remodeling 
of the inner retinal cells takes place early causing changes in the expression of 
transcription factors, which could account for the loss of specific expression with the 4x 
GRM6-SV40 promoter
14,15
. To address this concern, we tested the AAV8BP2 4xGRM6-
SV40-eGFP vector in different retinal degeneration mouse models (rd10, rd16 and 




eGFP expression (even with anti-GFP antibodies) in each of the strains of mice tested.  
Islands of eGFP expression were seen in each mouse line with bipolar cell expression 
observed along with expression in ganglion and amacrine cells (Figure 4).  Especially 
strong expression was seen in ganglion cells in the rd10 line (Figure 4e-h).  Overall, we 
observed a general misregulation of the 4xGRM6-SV40 promoter in four retinal 
degeneration mouse models that results in non-specific expression. 
It is also possible that the misregulation of gene expression is limited to the 4xGRM6-
SV40 promoter and to address this, we tested another bipolar cell specific promoter, 
TRPM1. Interestingly, TRPM1 expression is retained in the bipolar cells even after 
photoreceptor loss in the rd1 mice (Krizaj et al 2010). We cloned the human TRPM1 
promoter in front of CatCh-eGFP, packaged it into AAV7m8 and AAV8P2 and injected 
WT and rd1 mice between 3 and 4 weeks of age.  In wildtype retinas we observed ON-
bipolar cell specific expression with both AAV8BP2 and AAV7m8 (Figure 5a,b). We 
also observed expression in some cells of the outer nuclear layer and RPE with 
AAV7m8. In rd1 mice, however, AAV8BP2 only expressed eGFP in the RPE cells 
(Figure 5c), while with AAV7m8, a similar expression pattern in the inner retina as with 
the 4xGRM6-SV40 promoter was seen, with eGFP expressed in amacrine and few 
ganglion cells (Figure 5d). As with the 4xGRM6-SV40 promoter studies, we did not 
observe improvements in navigational vision (data not shown).  
To understand if these findings were species specific, we tested AAV7m8-TRPM1-
CatCh-eGFP in retinal explants of a Crd1 dog model of retinitis pigmentosa
16
. We found 




(Figure 5e). We also observed eGFP positive axon terminals in the inner plexiform layer. 
In previous studies we showed that the AAV8BP2-4XGRM6-SV40 promoter did drive 
expression in the ON-bipolar cells of the Crd1 dog post-injection but wasn’t specific to 
those cells (Ramachandran et al., 2016).  
In order to determine if we could target the ON-bipolar cells with a ubiquitous promoter 
more efficiently, we administered subretinal and intravitreal injections of AAV8BP2 and 
AAV7m8 with a ubiquitous (CMV/CBA) promoter driving expression of eGFP in rd1 
mice at six months of age.  Although the transduction efficiency was lower than 
previously seen in WT mice (data not shown), the viruses were still capable of 
transducing bipolar cells and more efficiently with AAV8BP2 when compared to 
AAV7m8 (Figure 6 a-d).  These studies suggest that while we can transduce the ON-
bipolar cells with a ubiquitous promoter in the degenerate retina, we may not be able to 
restore vision using optogenetic therapy if it requires cell specific expression.   
Discussion: 
Our studies show that the expression levels and expression pattern of the GRM6 and 
TRPM1 promoters are significantly altered in remaining retinal cells after photoreceptors 
have degenerated compared to that seen in wildtype retina.  This suggests that selecting 
promoters for optogenetic therapy based on expression patterns in a healthy retina is not 
the best strategy.  A more thorough understanding of gene expression in late stage retinal 
degeneration would allow for more informed selection of cell specific promoters.  The 




using the GRM6 promoter suggests that non-specific, low level expression is sufficient 
for visual function or that earlier stages of retinal degeneration retain enough GRM6 
promoter activity to allow for some retention of cell specific expression.  Further 
exploration of cell specific promoters in a degenerate retina could result in even better 
greater visual improvement after optogenetic therapy.   
A simplistic assumption is that after photoreceptor degeneration, the inner retina only 
experienced mild changes and remained, in essence, the same structurally and 
functionally as the inner retina of a healthy retina and simply lacked signal input.  This 
would be ideal for optogenetic therapy.  Simply add the signal at the appropriate place 
and it will be treated the same as the signal in a non-degenerate retina (minus any retinal 
processing that would have taken place at an earlier step).  This assumption has been 
disproven.  The inner retina only undergoes subtle changes during the early stages of 
retinal degeneration, but late stage retinal degeneration involves glial hypertrophy, cell 
migration, and ectopic synapse formation
17-24
.  These changes have the potential to 
drastically affect the utility of optogenetic therapy, especially cell specific optogenetic 
therapy.   
Glasauer et al created a transgenic zebrafish that showed expression of a GRM6 paralog 
not only in bipolar cells but also in a subset of ganglion and amacrine cells
25
.  It is 
possible that the nonspecific expression we see is due primarily to down regulation in the 
bipolar cells rather than up regulation in ganglion and amacrine cells.  However, the 
change in the expression profile of mGluR6 in advanced retinal degeneration has been 
seen in other studies
12




4xGRM6-SV40 promoter in rd1 mice, seeing even less bipolar cell expression than we 
saw, likely due to the fact that they administered the virus intravitreally while we used 
subretinal injections for AAV8BP2
12
.  Tehrani et al observed that mGluR6 was expressed 
in a subset of ganglion cells in rats following axotomy
26
.  It is also expressed in ganglion 
cells during development
26
.  This suggests that the retina deprived of input from the 
photoreceptors, may revert to a pseudo-developmental state.   
With the TRPM1 promoter, the results were surprising given the data from previous 
studies that endogenous TRPM1 expression is still cell specific and expression levels 
don’t change in rd1 mice
27
. It is possible that strain background differences or that 
exogenous promoter expression is modulated in these mice in retinal degeneration.  
The CMV promoter appears to be much more promising for optogenetic therapy in the 
retina.  Although it is non-specific, we were able to easily observe expression in the 
retina while both the GRM6 and TRPM1 expression appeared to be very low and required 
amplification with a GFP antibody to visualize.  Intravitreal injections can be used to 
largely limit the expression to ganglion cells.  Further studies will have to be done to 
determine whether a non-specific strategy is viable for vision restoration.   
Overall, it appears that the inner retina undergoes a substantial change in expression 
profiles that we do not yet understand.  Some studies have been done to look at the 
changes in gene expression patterns in the retina using microarrays
28,29
.  Those studies are 
a good first step towards evaluating the changes that occur in retinal remodeling, but they 




Comparing gene expression in a retina with and without photoreceptors will inherently 
show up regulation of inner retina genes and down regulation of photoreceptor genes 
simply because the photoreceptor population is either absent or greatly reduced.  In order 
to achieve a true comparison, photoreceptors would either have to be sorted out (possibly 
using fluorescence-activated cell sorting) or through single cell analysis.  The second 
major drawback of using pooled cDNA is that it will only show changes in the average 
gene expression and would not be able to determine if some cell types up regulate a gene 
while other cell types down regulate the same gene.  Part of what we saw was that the 
4xGRM6-SV40 promoter appeared to be down regulated in the bipolar cells and up 
regulated in amacrine and ganglion cells.  Another study was done using in situ 
hybridization in rd1 and WT mice to compare expression levels of 169 genes
30
.  This 
study provides better insight into the changes in the retina and can eliminate the 
confounding factors inherent in using pooled cDNA.  However, they can only evaluate 
one transcript at a time and cannot conclusively identify the identity of the inner nuclear 
layer cells.  Considering late stage retinal degeneration involves cellular migration, 
identification based on localization is especially risky.  Evaluating one transcript at a time 
eliminates the possibility of evaluating the concomitant up and down regulation of 
multiple transcripts within the same cell. 
More in depth study of the expression profiles of cells in the degenerate retina would help 
us to not only target specific cell types but also to better understand the cellular responses 
to photoreceptor degeneration.  It is possible that the4xGRM6-SV40 promoter is being 




in situ hybridization in rd1 mice at early and late stages of retinal degeneration could 
clarify whether there is up regulation of mGluR6 in other cell types.  Most importantly, 
selection of any cell specific promoters for use in a degenerate retina should be done in a 
retinal degeneration model as opposed to WT retina.   
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Figure 5-1: Expression profile of the 4xGRM6-SV40-CaTCH-eGFP construct in WT and rd1 mice.  
Note the strong and specific expression in the WT mice in contrast to the sparse amacrine cell 
expression in the rd1 mice.  A-C: WT mouse injected with AAV8BP2-4xGRM6-SV40-CaTCH-eGFP.  
D-F: Rd1 mouse injected with AAV8BP2-4xGRM6-SV40-CaTCH-eGFP.  G-I: Rd1 mouse injected 
with AAV7m8-4xGRM6-SV40-CaTCH-EGFP.  EGFP expression is seen in green and DAPI staining 






Figure 5-2: Comparison of young (injected at 1 month) and old (injected at 8 months) rd1 mice 6 
weeks after injection with the 4xGRM6-SV40- EGFP in AAV8BP2. GFP fluorescence is amplified 
by an anti-GFP antibody.  Note the primarily bipolar cell expression in the younger mice with 
more expression in the amacrine cells (white astrisks) in the older mice.  A-C and D-F: 1 month 
old rd1 mice injected with AAV8BP2-4xGRM6-SV40-eGFP.  G-I and J-L: 8 month old rd1 mice 




of the nucleus is in blue.  ONL: outer nuclear layer, INL: inner nuclear layer, GCL: ganglion cell 
layer. 
 
Figure 5-3: Variable expression is seen in the neural retina in different sections within the same 
eye.  All three sections are from a 1 month old rd1 mouse injected with 4xGRM6-SV40- EGFP in 
AAV8BP2.  Each row is a different section from the same eye.  GFP fluorescence is amplified by 
an anti-GFP antibody and choline acetyltransferase (CHAT) staining was performed to identify 
ON and OFF sublamina in the inner plexiform layer.  While some areas have primarily bipolar cell 
expression, other areas have expression in amacrine and muller glia cells.  Note the remnant 




row (H, white arrow) and the transduced amacrine cell (L, white arrow head).  EGFP expression 
is seen in green, ChAT is seen in red and DAPI staining of the nucleus is in blue.  ONL: outer 
nuclear layer, INL: inner nuclear layer, GCL: ganglion cell layer 
 
Figure 5-4: 4xGRM6-SV40- EGFP expression in various mouse models of retinal degeneration.  
The expression construct was administered via subretinal injection packaged in AAV8BP2 .  GFP 
fluorescence is amplified by an anti-GFP antibody and CHAT staining was performed to identify 
ON and OFF sublamina in the inner plexiform layer.  The expression was not bipolar cell specific 
in any of the mouse models.  The white arrows (D, H, L) indicate some of the ganglion cells 
expressing GFP.  EGFP expression is seen in green, ChAT is seen in red and DAPI staining of the 


























Figure 5-5: TRPM1 promoter driven expression in WT (a,b) and rd1 mice(c,d) and crd1 dog 
retinal explant cultures(e). AAV7m8 or AAV8BP2. eGFP expression is seen in green, GOalpha is in 










Figure 5-6: Comparison of tropism of different AAV capsids in rd1 mice.  A-D: Retinal cross-
section from adult rd1 mice injected with either AAV8BP2 (A and B) or AAV7m8 (C and D).  GFP 
expression was driven by the ubiquitous CMV/CBA promoter.  The virus was administered 
subretinally in A and C and intravitreally in B and D.  ONL: outer nuclear layer, INL: inner nuclear 
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Chapter 6: General Conclusions and Future Directions 
Filtering Whole Exome Sequencing Results: Advantages and Disadvantages 
Whole exome sequencing (WES) is a powerful tool that provides a very large data set.  
Everyone has many rare variants in their exome, most of which are completely benign.  
Even de novo variants are usually benign, with everyone having approximately 50 de 
novo variants on average with several variants in the exome
1
.  De novo variants are 
enriched in the exome considering that it makes up only 2% of the human genome, but 
even most variants in the exome are benign
2
.  The type of mutation also serves as a poor 
indicator of pathogenicity.  A severe mutation like a truncation and frameshift can be 
tolerated in some genes while a minor single nucleotide polymorphism (SNP) can be 
pathogenic if it is in an important position in the protein
3-5
.  Conservation of the sequence 
across species can give an indication of the likelihood that a mutation at that position can 
be tolerated with highly conserved areas less likely to tolerate alteration, but it is not a 
guarantee that a mutation will or will not be tolerated
6
.  Due to all this uncertainty, 
variant analysis cannot be fully automated.  Applying filters can make the list of potential 
pathogenic variants more manageable.  However, it is important to not be over-zealous in 
filtering the variants.  Filtering brings with it the risk of removing the pathogenic variant 
before analysis even begins.   
We found that screening for rare variants in a curated list of retinal genes already linked 
to retinal degeneration created a manageable list of potential variants, with usually less 
than 20 genes identified on each list, most of which could be eliminated quickly.  We did 




heterozygous.  We found that if we took inheritance pattern into account after looking up 
the rare variants instead of before, we avoided filtering out pathogenic variants.    This 
allowed us to identify two subjects with de novo dominant mutations as well as one 
subject diagnosed with multiplex RP who had multiple variants in several recessive 
genes, suggesting that the inheritance pattern in the family may not be dominant RP but 
rather a coalescence of several different forms of recessive RP.  It also avoids the 
differences in interpretation that can be caused by incomplete or inaccurate family history 
or, in cases where one or both parents are unknown (for example, an adopted child) as 
well as potential problems from a second variant that is not detected by WES  such as an 
intronic or a large copy number variant (CNV). 
Screening first for variants in genes already linked to retinal degeneration shortens the 
analysis time for subjects with easily identified mutations.  Many gene variants have been 
found that can cause multiple forms of retinal degeneration, depending on the exact 
mutation and the presence or absence of modifying alleles.  For example, PRPH2 can 
cause retinitis pigmentosa or macular dystrophy
7
.  BEST1 variants can cause vitelliform 
macular dystrophy, autosomal recessive bestrophinopathy, autosomal dominant 
vitreoretinochoroidopathy or retinitis pigmentosa
8
.  Therefore, screening all genes 
associated with retinal degeneration can identify novel phenotypes for mutations in genes 
already known to cause retinal degeneration.  Furthermore, incomplete medical or family 
history, examination at an early stage of disease or examination by someone other than a 
retinal degeneration specialist can lead to an incomplete or inaccurate diagnosis.  




out the pathogenic variant if the patient phenotype was mischaracterized, incomplete or 
continued to develop.   
Testing for Digenic Causes of Retinal Degeneration 
Possibly the most interesting finding was that several of the probands had multiple 
heterozygous mutations in retinal pathways.  These mutations, while pathogenic or likely 
pathogenic when homozygous, are generally tolerated in isolation.  However, the 
cumulative effect of multiple heterozygous mutations in the same pathway or protein 
complex has not been extensively studied.  So far, few digenic or polygenic causes of 
retinal degeneration have been identified.  This is in part due to the increased cost and 
complexity of studying the cumulative effect of multiple mutations in the same pathway.  
It is difficult to acquire enough patients with similar mutations and enough affected 
family members to determine whether the mutations are likely to be pathogenic when you 
are dealing with multiple genes instead of a single gene.  It will be important to test the 
effect of multiple mutations in the same complex.  With CRISPR becoming more 
widespread, we now have the tools to test the effect of heterozygous knockout in 
interacting proteins in cell culture and later in animal models.  One subject in our cohort 
had a potential digenic cause with heterozygous mutations in BBS2 and PCM1, which are 
both parts of the BBSome
9
.  Cell models created using CRISPR and zebrafish models can 
both be used to evaluate the effect of multiple heterozygous mutations in the BBSome on 
cilia structure and function
10-12




While evaluating the effect of combining specific mutations can be challenging in mice, 
evaluating the effect of combined null alleles is relatively simple.  There are many mouse 
models of homozygous null alleles for various genes.  In fact, both BBS2 and PCM1 have 
mouse models with null alleles
13,14
.  Crossing the two mouse lines will allow us to 
evaluate the effect of combined heterozygous loss of function mutations in two different 
genes.  This is an imperfect method for evaluating the mutations since a missense 
mutation could be acting as a dominant negative while a null mutation cannot.  On the 
other hand, if the missense mutation creates a hypomorphic allele evaluating the effect of 
a null allele could actually create a more severe model and reveal an effect where the 
missense mutations would not have a phenotype.  It is still worthwhile to study the 
combined effect of heterozygous null alleles to identify which genes will and will not 
have an additive effect from heterozygous loss of function alleles.   
Induced pluripotent stem cells (IPSCs) can be used to confirm a digenic cause of disease 
for cilia genes like BBS2 and PCM1.  The IPSCs can be differentiated to RPE or neural 
progenitor cells and then the effect of gene augmentation on the cilia can be evaluated
15
.  
If the cause truly is digenic, supplementation with either of the genes should reverse the 
cilia deficits.   
Of course, the effect of additional heterozygous mutations may be more subtle.  Some 
variants could be acting as disease modifiers, making the phenotype more or less severe 
but having no effect in an unaffected individual.  Modifying alleles can either affect the 
mutated proteins function or trafficking or they can act by affecting the expression level 




complicated without a large enough cohort of patients with the same mutation or a large 
family with multiple affected individuals participating in the study.   
Novel Gene Discovery 
Trios (the parents and the proband) are needed in order to identify novel pathogenic 
mutations.  Without trios we cannot be sure that the mutation segregates with the disease, 
which is step one in validating potential variants.  It is possible to identify novel 
pathogenic variants in genes already known to cause disease without parental DNA since 
we already have reason to suspect that a rare variant in that gene can cause a similar 
phenotype to that of the patient.  It can also be possible to identify novel genes if you 
have enough patients with the same diagnosis and a reason to believe that all or most 
would have the same genetic cause.  For example, if the disease has stereotypical 
symptoms, onset and progression it is more likely to have a single genetic cause than if 
the disease is highly variable in onset, progression, severity and symptoms.  In our case, 
we were studying a highly heterogeneous group and would not expect to see a high 
number of patients with the same novel genetic cause of their disease.  Without trios we 
cannot reliably differentiate between a novel but benign polymorphism and a pathogenic 
variant without investing significant time and resources into functional testing.  
Proceeding to functional testing without segregation analysis would result in a lot of dead 
ends, with most variants in novel genes likely not having a functional effect.   
In this project, we identified the patients in our cohort who are the best candidates for 




lead to retinal degeneration.  One method of screening for novel genes is to filter based 
on genes expressed in the retina.  The retinome has been identified and can easily be used 
as a filter
24
.  However, this results in a very large list of genes, including many that are 
not expressed in cell types likely to lead to the types of retinal degeneration we are 
studying.  For example, mutations in bipolar cells can cause congenital stationary night 
blindness, but would likely not cause primary photoreceptor degeneration
25
.  Instead of 
using such a broad set of genes to filter the results, we will be using lists of genes in the 
same pathway as genes that have been shown to cause retinal degeneration.  Since we 
maintain the lists separately, we can prioritize genes based on the specific diagnosis.  If 
we are unable to identify a likely pathogenic mutation from the pathway based analysis, 
we can then broaden the search to include all genes known to be expressed in the RPE 
and photoreceptors.   
The Limits of Whole Exome Sequencing 
WES has a few well known limitations.  The primary drawback is that we are unable to 
detect intronic variants using WES.  This is usually not a problem since the majority of 
pathogenic variants are located in the exome or splice sites (which are included in WES).  
Some genes, like CEP290 and ABCA4 have been shown to have pathogenic mutations in 
the introns
16,17
.  Patients with LCA should always be screened for the deep intronic 
variant in CEP290 before WES due to its particularly high frequency.  Another type of 
mutation that is missed by WES are copy number variants (CNVs).  With sufficient depth 
of coverage it is possible to see evidence of likely CNVs with WES but that is currently 
not a reliable method of detecting CNVs
18,19




effective method of detecting pathogenic variants in most cases due to the rarity of CNVs 
and intronic variants.  If a pathogenic heterozygous variant is identified, the gene should 
be screened for CNVs and intronic variants.  If no likely pathogenic variants are 
identified by WES, it then makes sense to use WGS to try to find intronic mutations and 
CNVs. 
Some diseases are not well suited for WES.  Mutations in only three different genes have 
been shown to cause Stargardt disease, with the majority of patients having mutations in 
ABCA4
20-22
.  If the initial panel screening genes associated with Stargardt/macular 
dystrophy comes back negative, it would be more cost and time effective to then do a 
complete screening of ABCA4 for intronic variants and CNVs than to perform WES.  
Only if those screens come back negative would it make sense to proceed to whole 
exome sequencing.  Choroideremia is only known to be caused by mutations in CHM, 
many of which involve large deletions
23
.  Evaluating choroideremia patients with WES 
would provide less information at a higher cost than a thorough screening of CHM.   
Characterization of Gene Expression During Retinal Degeneration: An 
Interrogation using GRM6 
In addition to identifying pathogenic mutations, next generation sequencing can be used 
to better understand the changes that occur in the retina during retinal degeneration.  As 
we saw when we used the 4xGRM6-SV40 promoter, retinal cells undergo profound 
structural and functional changes during degeneration.  Although the inner retinal cells 




allow us to see changes in the entire transcriptome rather than evaluating gene expression 
on a gene by gene basis.  Evaluating the transcriptome of the retina as a whole would be 
misleading due to the loss of the photoreceptors.  A relative upregulation of proteins 
expressed in the inner retina is to be expected since the cell population would be enriched 
for those cells. Performing RNA-Seq using the entire retina would also prevent us from 
being able to determine if the transcripts are being expressed in different cell types than 
in the healthy retinal cells.  Single cell analysis allows us to see the number and type of 
cells expressing each transcript as opposed to total transcript amount.   
The expression profile of the 4xGRM6-SV40 promoter appears to be similar to the 
expression profile of GRM6 during development.  While mGluR6, the protein encoded 
for by GRM6, is restricted to ON bipolar cells in healthy adult retina, it was seen in rat 
retinal ganglion cells both during retinal development and post-axotomy in WT mice
26,27
.  
It is also upregulated in response to increased retinal pressure
27
.  Importantly, in our gene 
transfer study in the rd1 mouse, the drastic dysregulation of the promoter does not appear 
to occur until there is complete loss of cone photoreceptors.  In order to thoroughly 
evaluate the effect of retinal degeneration on the expression profile of the GRM6-SV40 
promoter, we could cross the rd1 mouse line with the transgenic mouse line expressing 
GFP under the GRM6-SV40 promoter.  Using a transgenic mouse line would eliminate all 
confounding factors such as viral tropism, age at injection and uneven viral distribution 





Optimizing Optogenetic Therapy in Light of Retinal Remodeling 
While retinal remodeling affects the expression profile of the cells in the retina, it is also 
likely that optogenetic therapy will have an effect on retinal remodeling.  The earliest 
stage of retinal remodeling in rod dystrophy is for the rod bipolar cells to form synapses 
on the cones
28
.  It is possible that if we introduce channelrhodopsin in the ON bipolar 
cells, it could cause ectopic synapse formation onto the ON bipolar cells, which could 
cause problems with retinal processing and degrading the visual signal.  The best way to 
evaluate this would be to create a transgenic mouse line expressing channelrhodopsin 
under the GRM6-SV40 promoter using the rd1 mouse strain
29
.  This would allow us to 
model the effect of exogenous opsin expression without including the potential variables 
introduced by subretinal injection and viral transduction.   
AAV8b was developed through directed evolution specifically to target bipolar cells
30
.  If 
we want to target bipolar cells in the degenerate retina, directed evolution should be done 
using a degenerate retina to account for the changes in receptor expression which are 
likely to affect viral tropism.  Based on our results, optimizing viral tropism for the WT 
retina does not appear to translate well to the degenerate retina.  Using cultured human 
retinal explants from donors with retinal degeneration would be the most accurate way to 
predict which viral capsid will target human bipolar cells effectively.  Additionally, we 
should use a mouse model of retinal degeneration like the rd1 or rd10 strains since the 
presence of RPE and overall ocular environment may affect viral transduction efficiency.  
Ideally, the capsid selected should work well in both mice with retinal degeneration and 




shown here, using WT mice should be avoided as a model for optimizing optogenetic 
therapy. 
Assuming that promoter expression profiles will be the same in healthy and degenerate 
retina has also been shown to be misleading.  Instead, promoter selection and 
optimization should occur in the tissue type and state that will be used.  Human retinal 
explants from donors with retinal degeneration could be used for initial promoter 
screening.  A single retina can be cultured in multiple wells, allowing for a more efficient 
screen.   
General Conclusion 
If we want to be able to treat inherited retinal degenerations, we will need to better 
understand both the genetics of the disease(s) and the changes that occur in the retina 
during late stage retinal degeneration.  Gene augmentation is still the best potential 
treatment option for retinal degeneration, but requires the accurate identification of the 
pathogenic mutations/genes.  In the era of personalized medicine, we are making great 
strides towards the goal of identifying the pathogenic mutation in every patient, but we 
still need to optimize the genetic screening to minimize the amount of time needed to 
analyze the results and to filter the variants to a manageable list.  Late stage treatment 
will require a thorough understanding of the retina in an advanced stage of degeneration.  
Optimization of both viral serotype and promoters in degenerate retina will need to be 
done for the best chance of success. The potential effect of optogenetics on retinal 
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